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1. Abstract 
 
Cervical cancer is thought to be the consequence of infection by 
human papillomaviruses (HPV).  In the majority of cases, DNA from HPV type 16 
(HPV16) is found in malignant cervical lesions.  The initial steps leading to 
transformation of an infected cell are not clearly understood but in most cases, 
disruption and integration of the episomal viral DNA must take place.  As a 
consequence, the E2 and E4 genes are usually not expressed whereas the E6 
and E7 oncogenes are highly expressed.  However, in a normal infection in 
which the viral DNA is maintained as an episome, all viral genes are expressed.   
The pattern according to which the viral proteins are made, and 
therefore the life cycle of the virus, is tightly linked to the differentiation process of 
the host keratinocyte.  The study of the viral oncogenes E6 and E7 has revealed 
crucial functions in the process of malignant transformation such as degradation 
of the p53 tumor suppressor protein, deregulation of the Retinoblastoma protein 
pathway and activation of the telomerase ribonucleoprotein.  All these steps are 
necessary for cancerous lesions to develop.  However, the loss of the E2 gene 
product seems to be necessary for sufficient expression of E6 and E7 in order to 
achieve such effects. 
In normal infections, the E4 protein is made abundantly in the later 
stages of the viral life cycle.  Though extensive amounts of work have been 
carried out to define the function of E4, it still remains unclear.  In this study, 
several approaches have been used to try and determine the functions of E4. 
First, a cell-penetrating fusion protein was designed and produced in 
order to circumvent the chronic difficulties of expressing E4 in mammalian cells.  
Unfortunately, this approach was not successful due to precipitation of the 
purified fusion protein. 
Second, the observation that E4 accumulates in cells having modified 
their adhesion properties led to the hypothesis that E4 might be involved in the 
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differentiation process of keratinocytes.  Preliminary results suggest that E4 
triggers differentiation. 
Last, as E4 has been reported to collapse the cytokeratin network of 
keratinocytes, a direct approach using atomic force microscopy has allowed us to 
test the potential modification of mechanical properties of cells harboring 
reorganized cytokeratin networks.  If so, a potential role for E4 in viral particle 
release could be hypothesized. 
 
 
2. Résumé 
 
Il a été établi que le cancer du col de l’utérus se développe 
essentiellement à la suite d’une infection par le virus du papillome humain (HPV).  
Dans la majorité des cas analysés, de l’ADN du HPV de type 16 (HPV16) est 
détecté.  Les étapes initiales de la transformation d’une cellule infectée sont mal 
connues mais il semble qu’une rupture du génome viral, normalement épisomal, 
suivi d’une intégration dans le génome de la cellule hôte soient des étapes 
nécessaires dans la plupart des cas.  Or il semble qu’il y ait une sélection pour 
les cas où l’expression des oncogènes viraux E6 et E7 soit favorisée alors que 
l’expression des gènes E2 et E4 est en général impossible.  Par contre, dans 
une infection dite normale où le génome viral n’est pas rompu, il n’y pas 
développement de cancer et tous les gènes viraux sont exprimés. 
L’ordre dans lequel les protéines virales sont produites, et donc le 
cycle de réplication du virus, est intimement lié au processus de différentiation 
differentiation de la cellule hôte.  L’étude des protéines oncogènes E6 et E7 a 
révélé des fonctions clés dans le processus de transformation des cellules 
infectées telles que la dégradation du suppresseur de tumeur p53, la 
dérégulation de la voie de signalisation Rb ainsi que l’activation de la télomérase.  
Toutes ces activités sont nécessaires au développement de lésions 
cancéreuses.  Toutefois, il semble que l’expression du gène E2 doit être 
empêchée afin que suffisamment des protéines E6 et E7 soient produites.   
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Lorsque le gène E2 est exprimé, et donc lorsque le génome viral n’est 
pas rompu, les protéines E6 et E7 n’entraînent pas de telles conséquences.  Le 
gène E4, qui se trouve dans la séquence codante de E2, a aussi besoin d’un 
génome viral intact pour être exprimé. 
Dans une infection normale, le gène E4 est exprimé abondamment 
dans les dernières étapes de la réplication du virus.  Bien que de nombreuses 
études aient été menées afin de déterminer la fonction virale à E4, aucun résultat 
n’apparaît évident.  Dans ce travail, plusieurs appoches ont été utilisées afin 
d’adresser cette question. 
Premièrement, une protéine de fusion TAT-E4 a été produite et 
purifiée.  Cette protéine, pouvant entrer dans les cellules vivantes par diffusion 
au travers de la membrane plasmique, aurait permis d’éviter ainsi les problèmes 
chroniques rencontrés lors de l’expression de E4 dans les cellules mammifères.  
Malheureusement, cette stratégie n’a pas pu être utilisée à cause de la 
précipitation de la protéine purifiée. 
Ensuite, l’observation que E4 s’accumule dans les cellules ayant 
modifié leurs propriétés d’adhésion a suggéré que E4 pourrait être impliqué dans 
le procédé de différentiation des kératinocytes.  Des résultats préliminaires 
supportent cette possibilité. 
Enfin, il a été montré que E4 pouvait induire une réorganisation du 
réseau des cytokératines.  Une approche directe utilisant le microscope à force 
atomique nous a ainsi permis de tester une potentielle modification des 
propriétés mécaniques de cellules ayant modifié leur réseau de cytokératines en 
présence de E4.  Si tel est le cas, un rôle dans la libération de particules virales 
peut être proposé pour E4. 
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3. Introduction 
3.1. Cancers 
 
Along with stroke and myocardial disabilities, cancer is one of the most 
important causes of death worldwide.  As the disease usually takes some time to 
appear, its prevalence depends not only on the geographical situation or life-
style, but also on the mean age, or the life expectancy, of the population. 
Therefore, cancer is often thought of as being a disease associated with 
developed countries. 
Cancer in itself is not a unique disease: there are a very large variety 
of cancers.  Their classification often refers to the tissue or organ in which it 
appears.  Due to smoking and increasing air pollution, lung cancers are currently 
increasing and becoming the most frequent type of cancer worldwide.  Among 
the female population, the most prevalent is breast cancer, followed by cervical 
cancer whose cause will be the focus of this thesis.  Cancers all derive from a 
small number of cells that have acquired sufficient mutations to escape the 
control of the cell-cycle machinery and go through uncontrolled and repeated 
division cycles, which in turn leads to an increasing tumor mass and malfunction 
of the organ (Nowell, 1976).  It has been estimated that six to eight events are 
necessary to transform a normal cell into a cancer cell (Hahn et al., 1999; Hahn 
and Weinberg, 2002).  These events include evading apoptosis, self-sufficiency 
in growth signals, insensitivity to anti-growth signals, limitless replicative 
potential, sustained angiogenesis and tissue invasion and metastasis (Hanahan 
and Weinberg, 2000).  As the immune system is able to target cells expressing 
unusual proteins, these transformed cells also escape immune surveillance.  In 
some cases, a transformed cell may leave the original tumor, migrate to another 
organ and establish a second tumor: metastasis has begun.  In this situation, the 
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disease has reached a critical stage and its therapy becomes much more 
difficult.   
Most people will agree in saying that “prevention is better than cure”.  
To design rational strategies to prevent such malignancies would therefore be of 
the highest priority.  Such strategies necessitate a thorough understanding of the 
pathogenesis of the various cancers. 
 
 
3.2. Viruses and cancer 
 
Over the past three decades, an accumulation of evidence supports 
the hypothesis that many human malignancies arise, at least in part, from a 
range of virus infections (Meisels and Fortin, 1976; Swanton and Jones, 2001).  It 
has been proposed that viral infections are the cause of 15% of human cancers 
to date (zur Hausen, 1999).  
For a virus to induce uncontrollable cell proliferation, at least three 
different processes must take place (Irving and Thomson, 2001).  The virus must 
first be able, directly or indirectly, to uncouple the normal cell-cycle and cell 
division regulatory mechanisms.  Second, the virus must prevent the occurrence 
of apoptosis, which is the normal cellular response to the uncoupling of the 
regulatory mechanisms that control cell-cycle and cell division, as well as to viral 
infections.  Finally, the infected cell, which exposes viral antigens on its surface, 
must not be recognized by the immune system as foreign.   
A number of viruses that have been identified are able to perform 
these three crucial steps: human papillomaviruses can induce carcinoma of the 
uterine cervix, hepatitis B and C viruses can induce hepato-cellular carcinomas, 
human T-cell lymphotrophic virus type 1 can induce T-cell lymphoma/leukemia, 
Epstein-Barr virus can induce a variety of lymphomas and carcinomas, and 
human herpesvirus type 8 (Kaposi’s sarcoma associated human herpesvirus) 
can induce Kaposi’s sarcoma.  Also, some non-human viral proteins are able to 
transform human cells (for example SV40 large T / SV40 small t). 
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The strategies used by these viruses often overlap, suggesting some 
of the targeted pathways are crucial and must be affected in order to allow the 
malignancy to develop.  
One of the commonly affected pathways is the Retinoblastoma (Rb) 
pathway.  EBNA3C and LANA of the Epstein-Barr virus (Hollyoake et al., 1995), 
HPV E7 (Brehm et al., 1998), SV40 large T (reviewed in (Barbanti-Brodano et al., 
2004), HTLV-1 Tax (Low et al., 1997; Suzuki et al., 1996) for instance are viral 
proteins preventing the Rb protein or its pathway from functioning normally, 
releasing unusual amounts of the E2F transcription factor which leads to 
premature S-phase entry.  The direct targets of the viral proteins vary but almost 
always affect the phosphorylation state of Rb.  This takes place by affecting 
cyclin dependent kinases or phosphatases, which either phosphorylate or 
dephosphorylate Rb respectively.    
A second pathway often affected by viruses is that of the tumor 
suppressor p53.  SV40 large T, HPV E6 (reviewed in (Mantovani and Banks, 
2001), and latency-associated-nuclear-antigen (LANA) (Katano et al., 2001) of 
the Epstein-Barr virus abrogate p53’s tumor suppressor activity.  The levels of 
the p53 target p21 are no longer regulated, and the cell cycle does not respond 
to DNA-damage signals. 
It is of importance to remember that these viral activities are not always 
meant to lead to transformation of the host cell, but rather to push the cell 
towards a context allowing the virus to replicate rapidly.  Nevertheless, inhibition 
of the two pathways mentioned above contributes to genomic instability, which 
could hence lead to malignant transformation by allowing the accumulation of 
mutations.  It has been proposed that the minimal number of “hits” (mutations) 
allowing a fully transformed phenotype must be 5-6, depending on the cell type.  
All these hits are found to affect signaling pathways involved in either cell-cycle 
check points or chromosome integrity and protection (such as telomerase 
activation).  
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3.3. HPVs and cancer 
 
As mentioned above, cervical cancers show a high prevalence.  Close 
to 500’000 new cases appear every year, with a mean age of patients of 52 
years.  These malignancies are the fifth highest cause of female cancer-
associated deaths worldwide (Globocan 2002 IARC database, http://www-
depdb.iarc.fr/globocan/GLOBOframe.htm).  In over 99% of cervical cancers 
examined up to now, HPV DNA is found (de Villiers et al., 1981; Gissmann and 
zur Hausen, 1980; Walboomers et al., 1999).  There are over 200 HPV types 
identified to date (Munger et al., 2004), but HPV type 16  DNA is found in 50% of 
cervical cancers.  Risk factors for the development of tumors include having a 
large number of sexual partners.  Genital warts are one of the most commonly 
transmitted sexual diseases, and about 1 young adult in 200 is affected (Gross 
and Barrasso, 1997).  Table 1 summarizes the HPV types found in cervical 
cancers.  
HPV types found in cervical cancers
50%
14%
8%
5%
23%
HPV 16
HPV 18
HPV 45
HPV 31
Other
 
 
 
 
HPVs are small DNA tumor viruses about 50 to 60 nm in diameter (Fig. 1).   
                    
Table 1: Major HPV types found in cervical cancers. (Adapted from 
http://www-depdb.iarc.fr/globocan/GLOBOframe.htm ) 
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The viral genome is a circular double-stranded DNA, about 8 kb in size 
and comprising 8 open reading frames (ORF).  The DNA can be separated into 
three regions: the first encodes the early genes (E1, E2, E4, E5, E6 and E7), the 
second encodes the two late genes (L1 and L2) and the third is known as the 
long control region (LCR), where the replication origin and regulatory sequences 
are found.  Figure 2 shows a schematic and linearized model of the HPV16 
genome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: HPV viral particle: the left panel shows an electron micrograph, 
the right panel a reconstructed structure showing the L1 major capsid 
protein.  Adapted from 
http://www.rivm.nl/infectieziektenbulletin/bul1406/art_effectief.html and 
http://bilbo.bio.purdue.edu/~baker/projects/papova/papilloma/hpv_108
10.html  
Kb       0                1                2                3               4                 5                  6                  7                 7.9
RF1 
 
RF2 
 
RF3 
LCR 
E7               E1                                     E5              L2 
E6                                                    E2                                                        L1 
E4 
Fig. 2: Schematic linear representation of the HPV16 genome.  The 8 ORF are shown as 
well as the LCR.  Notice the use of the three possible reading frames. 
Organization of the HPV16 genome 
                Early region                                                  Late region 
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In a normal infection, also known as productive infection, the virus’ 
genome is maintained in an episomal state.  But in some cases, the episome 
may be disrupted and become linear.  This is a prerequisite to the integration of 
the viral genome in the host cell (Jeon and Lambert, 1995).  The two events of 
linearization and integration into the host’s chromosome are poorly understood, 
but seem to be necessary steps in order to lead to malignancy (Fig. 3), though 
cases of malignancies without integration have been reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Though these events are not well understood, some common features 
are found among various cervical cancer biopsies: 
 
a) The E6 and E7 genes must be expressed in sufficient amounts; 
b) E2 and E4 gene products are almost never found. 
 
Many studies have been aimed at an understanding what functions of 
the E6 and E7 oncoproteins are necessary for a malignant phenotype.  Though 
some differences are found between the HPV types, many features are 
Fig. 3: HPV DNA is frequently linearized and 
integrated into the host’s chromosome in 
order to lead to a malignant phenotype. 
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conserved.  The concerted action of these proteins always leads to an “S-phase-
like” environment, allowing the virus to use efficiently the cellular machinery to 
replicate its genome.  For this, the presence of the E1 and E2 gene products is 
also necessary.  But in the case of integrated viral DNA, E2 is often absent and 
the E1 protein either absent or present at very low levels.  From the malignancy 
point of view, the action of uncontrolled E6 and E7 expression will push the cell 
to replicate its genome without obeying the usual check-point signals or taking 
enough time to repair potential replication mistakes.  In turn, this could lead to an 
increased rate of cellular division, to immortalization, where cells expand their life 
span, and to mutations allowing malignant progression to take place. 
As the E2 and E4 gene products are often absent in cervical cancers, 
these proteins are thought of as being incompatible with cell growth.  A large 
amount of work has been done in this perspective, particularly on the E2 gene 
product.  It has been suggested that presence of E2 in cells does induce 
apoptosis in a p53-independent manner (Dowhanick et al., 1995; Goodwin et al., 
2000) as well as in a p53-dependent manner (Webster et al., 2000).  The 
presence of E4 in some cell types has been proposed to induce a G2-arrest of 
the cell cycle (Davy et al., 2002).  If so, the presence of E2 and E4 in cells will 
impede on the development of transformed malignancy by preventing the cell 
from dividing.  
 
 
3.4. HPVs and the HPV16 life-cycle 
 
As mentioned above, there are close to 200 different HPV types 
identified to date.  These viruses infect stratified epithelium.  Classification of 
HPVs is based on mainly two properties: 
 
a) Does the virus infect cutaneous or mucosal stratified epithelium? 
b) Is the propensity of the virus to induce cellular transformation high (high-
risk) or low (low-risk)? 
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The infected epithelia are mostly those of the anogenital tract, the 
hands or the feet, but viruses can also be found in the oropharynx.  The large 
majority of the high-risk HPV infect the mucosal stratified epithelium.  Table 2 
shows examples of HPV types. 
 
 
 
 
 
 
 
 
 
 
Infection of the genital tract by HPVs can initially result in low-grade 
lesions termed dysplasias or cervical intraepithelial neoplasia grade I.  These 
lesions show only mild alterations of the epithelial differentiation pattern and 
many of them are cleared by the immune system within a year (Huibregtse et al., 
1993; Jenson et al., 1991).  The mechanism by which the immune system 
responds to HPV infection is poorly understood.  However, some lesions are not 
cleared by the immune system and the virus can persist in a host cell for 
extended periods of time, up to decades.  The persistence of infection by a high-
risk virus is the most dangerous situation, and could lead to genital malignant 
transformation such as squamous cell carcinoma or adenocarcinoma of the 
cervix. 
The sequence homology among the different HPVs is not very high.  
This is one of the reasons they are classified into so many types.  It also makes 
each virus unique and it is therefore not always possible to use one of them as 
the working model for another. 
            HPV type 
High-risk     16, 18, 31-35, 45, 51, 52, 56, 58, 66, 68, 70, 73   
Low-risk     6, 11, 40, 42, 44, 53-55, 57, 59, 67, 69, 71, 74, 82    
Table 2: Classification of some mucosal HPV types (McMurray et al., 2001) 
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The life cycle of HPVs is not precisely known.  Nevertheless, it is tightly 
linked to the differentiation of the host epithelial cell.  A model for the life cycle of 
HPV16 is shown in figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not much is known about receptors for viral uptake.  Though it has 
been reported that HPV11 binds heparin and cell-surface glycosaminoglycans 
(Joyce et al., 1999), the proposed receptor for HPV type 6b entry is the integrin 
heterodimer α6β4 (Evander et al., 1997).  These integrins are only found on the 
surface of cells from the basal layer of the stratified mucosal epithelium (Pritinder 
and Li, 2000; van der Flier and Sonnenberg, 2001; Watt, 2002a).  Therefore, a 
micro-lesion is necessary for the virus to contact such receptors.  Once the virus 
has entered a cell, it travels to the nucleus and releases its DNA associated with 
histones in the form of mini-chromosomes.  Early viral proteins are then 
expressed (E1, E2, E6 and E7). The episome can be amplified to about 50 
copies per cell (Conger et al., 1999; Frattini and Laimins, 1994; Longworth  and 
HPV particles
Basal Layer 
Spinous layer 
Granular layer 
Cornified layer 
E2, E1 E6, E7E4 L1, L2
E2, E1
E2, E1
E2, E1 E6, E7
E6, E7
E6, E7
HPV16 DNA 
Fig. 4: Model of the HPV16 life cycle.  The initial infection is thought to occur through micro-
lesions of the epithelium in order for the virus to infect cells from the basal layer.  As the host 
cell differentiates and migrates towards the lumen of the cervix, viral proteins are expressed 
and viral DNA is amplified.  In cells undergoing terminal differentiation, the capsid proteins are 
produced and viral particles are assembled. 
E4
Basal lamina 
Fibroblast 
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Laimins, 2004; Mohr et al., 1990).  In this situation, the virus can be maintained 
as an episome for extended periods of time, up to several decades (Stubenrauch 
and Laimins, 1999).  Apart from the need for E1 and E2 proteins, the mechanism 
for the maintenance of the viral episome at low copy number remains unclear. 
If the cell containing the episome begins its differentiation process, a 
subset of differentiation-dependent viral promoters is also activated and other 
viral proteins are made.  Though differentiating cells do not normally replicate 
their DNA, the presence of E6 and E7 forces the cell to produce the elements 
necessary for DNA replication and provide the needed milieu for viral 
amplification.  The levels of E1 and E2 being sufficient, viral episomes can 
efficiently be amplified to high amounts thanks to the late S-phase imposed by 
E6 and E7 (Laimins, 1996).  In parallel, high amounts of E4 are produced.  It has 
been suggested the levels of E4 are so high they could represent up to 20% of 
the cell’s total protein (Breitburd et al., 1987; Doorbar et al., 1986).  Though initial 
analysis did not show this, it is now accepted that E4 may be produced in earlier 
stages of the viral life cycle but to a lesser extent than in differentiating cells.  The 
late capsid proteins (L1 and L2) are made in terminally differentiating epithelial 
cells, enabling viral DNA to be packaged and viral particles to be assembled (Liu 
et al., 2001).  The pattern of expression of the viral genes implies the use of 
several promoters, regulated differently.  A number of minor promoters have 
been identified, also playing an important role during the viral life cycle (Ozbun 
and Meyers, 1998). 
HPVs are not lytic viruses, hence the release of newly made viral 
particles does not occur through active disruption of the cell.  Terminally 
differentiated cells containing newly made viral particles are shed from the 
epithelium.  The mechanism by which viruses are released into the environment 
is not known.  Actually, many mechanisms of the late stages of the viral life cycle 
are poorly understood. 
An important difficulty in the study of HPV16 is the lack of an efficient 
protocol to grow viruses in vitro.  As the life cycle of HPV16 takes place in 
differentiating epithelia, methods such as organotypic raft cultures of 
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keratinocytes need to be used.  But such methods do not always show the 
complete process of differentiating epithelium as would be needed to study 
HPV’s life cycle.  There is also no mouse model allowing in vivo studies except 
using grafts in immuno-deficient mice.  Therefore, most of the results are 
obtained with cultured cells or in vitro assays using single-gene expression or 
combinations of single-gene expression systems. 
 
 
3.5. Viral proteins 
 
3.5.1. The E1 protein 
The E1 protein is about 70-80 kDa in size, its level of expression is 
quite low and its presence is essential for viral replication to occur (Ustav and 
Stenlund, 1991).  It is well conserved among the different human 
papillomaviruses as well as in the bovine papillomavirus (BPV).  This feature 
makes it possible to use the BPV E1 protein as a model for the HPV versions of 
E1.  It also shares some sequence homology and function with the large T 
antigen from SV40 and polyomavirus (Clerant and Seif, 1984; Mansky et al., 
1997).   
E1’s function in replication first begins when E2 interacts with E1 
(Yasugi et al., 1997) and helps in targeting it to an 18-nucleotide-specific 
sequence found at the origin of replication in the LCR of papillomavirus DNA 
(Holt et al., 1994).  This specific sequence is located right beside an E2 binding 
site.  Once E1 is bound to its target sequence, the recruitment of chaperone 
proteins such as Hsp70 and Hdj2 displaces E2 (Lin et al., 2002).  E1 units can 
subsequently be recruited to form hexameric rings around the viral DNA.  When 
two parallel rings are formed, bi-directional replication can be initiated.  ATPase 
activity has been located to the C-terminal region and is the source of energy for 
E1’s helicase unwinding function (Hughes and Romanos, 1993; Seo et al., 1993; 
Yang et al., 1993).  E1 also interacts with the cellular DNA polymerase α and 
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hSNF5, which is a component of the Swi/Snf complex (Lee et al., 1999).  These 
partners are involved in chromatin structure destabilization.  The binding of E2 
and polymerase α to E1 are mutually exclusive. 
 
3.5.2. The E2 protein 
In the E2 protein, three regions can be distinguished:  the N-terminal 
region, the hinge region and the C-terminal region.  The N- and C-terminal 
regions are well conserved among HPVs, while the hinge region shows more 
heterogeneity.  The N-terminal region is involved in transactivation and DNA 
replication, while the C-terminal domain is essential for DNA binding (Francis et 
al., 2000). 
E2 is a nuclear protein and is most often found as a dimer (Antson et 
al., 2000; Lima et al., 2000).  As mentioned above, E2 is essential in the 
replication of the viral genome through its interaction with the E1 protein.  The 
LCR contains four E2 binding sites (E2BS1-4) also involved in transcription 
activity.  E2 shows different affinities to the E2BSs and, depending on the 
concentration of E2, not all binding sites will be occupied.  At low concentration, 
E2 binds the E2BS 3 and 4, which are located away from the early promoter p97.  
Hence, recruited cellular transcription factors can bind and activate transcription 
(Li et al., 1991; Steger and Corbach, 1997).  When the E2 concentration is high, 
all four E2BSs are occupied and the cellular transcription factors such as Sp1 
and TFIID/B are displaced from the adjacent Sp1-binding site TATA-box.  In this 
situation, E2 acts as a transcriptional repressor (Romanczuk et al., 1990; Thierry 
and Howley, 1991).   
The negative regulation of the early promoter by high concentrations of 
E2 is easy to understand, but the activation has been the focus of much 
research.  It appears E2 has many cellular binding partners shown to elicit 
transcription efficiently, such as AMF1 (Breiding et al., 1997), TATA-binding 
protein (TBP) (Steger et al., 1995), TFIID (Rank and Lambert, 1995), p300/CBP 
(Lee et al., 2000a), p/CAF (Lee et al., 2002a), SMN (Strasswimmer et al., 1999), 
SP1, NF1/CTF(Ushikai et al., 1994), TEF1, upstream stimulating factor (USF) 
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and BRCA1 (Kim et al., 2003).  The activation of transcription seems therefore to 
occur through the interaction and recruitment of a large variety of cellular 
transcription activators (Ham et al., 1991).  This feature also necessitates a rapid 
turnover of the protein for efficiently controlled expression of the viral genes.  
Indeed, the half-life of E2 is relatively short and regulated through the 
proteasome pathway (Bellanger et al., 2001).  It is of importance to add that the 
transcriptional effects of E2 concern the integrated form of viral DNA.  When the 
viral DNA is episomal, the transcriptional regulation of E6 and E7 genes by E2 is 
absent (Bechtold et al., 2003). 
Apart from cellular transcription activators, E2 has also been shown to 
bind factors involved in DNA-damage signaling pathways, such as p53 (Massimi 
et al., 1999), topoisomerase-II-β-binding protein (Boner et al., 2002) or poly 
(ADP-ribose) polymerase (Lee et al., 2002b).  Nevertheless, no function in the 
viral life cycle of these interactions has been identified. 
 
3.5.3. The E5 protein 
The E5 protein is a small 10 kDa hydrophobic protein.  Its function in 
the HPV life cycle is unclear.  In bovine papillomaviruses (BPV), the E5 protein is 
the major transforming factor (reviewed in (Campo, 2002), but there seems to be 
no conservation between BPV and HPV for E5.  Localization studies have 
reported that human papillomavirus type 16 E5 seems to interact with the 
vacuolar H+-ATPase (Andresson et al., 1995; Straight et al., 1995). 
In vitro studies have also shown that HPV E5 localizes to endosomal 
membranes and to the Golgi apparatus (Oetke et al., 2000).  It has also been 
suggested that E5 increases cellular proliferation in the presence of EGF.  This 
could be exerted by interacting directly with the EGFR, PDGFβR, colony-
stimulating factor-1 receptor and p185neu (Hwang et al., 1995) and by slowing 
down the degradation of such receptors.   
When HPV E5’s effects on cell cycle are analyzed, it seems E5 has a 
function in maintaining a proliferative state of keratinocytes undergoing 
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differentiation and favoring late viral gene expression (Fehrmann et al., 2003).  
An anti-apoptotic effect of HPV E5 has also been reported (Kabsch et al., 2004). 
Recently, findings suggest HPV E5 might be involved in the escape 
from the immune surveillance by causing retention of the MHC class I in the 
Golgi apparatus, impeding their transport to the cell surface (Ashrafi et al., 2005).   
 
3.5.4. The E6 protein 
HPV E6 is one of the first proteins to be produced upon HPV infection 
(Sun et al., 1997).  HPV16 E6 is 151 amino acids in length, and it contains two C-
X-X-C Zn-binding motifs.  This feature is conserved among many HPVs and 
suggests an important function in the viral life cycle (Barbosa et al., 1989; Cole 
and Danos, 1987).  HPV16 E6 is found both in the nucleus and in the cytoplasm 
of infected keratinocytes.  HPV16 E6 alone is capable of transforming NIH3T3 
cells and immortalizing human mammary epithelial cells (Band et al., 1991; 
Wazer et al., 1995).  But alone it is not able to immortalize keratinocytes, the help 
of E7 being also needed (Hawley-Nelson et al., 1989; Munger et al., 1989b). 
High-risk HPV E6 has been shown to interact with many different 
proteins, such as the E6-associated protein (E6AP), a ubiquitin ligase 
(Huibregtse et al., 1993; Nuber et al., 1998; Schwarz et al., 1998).  The E6 and 
E6AP heterodimer then targets p53 for degradation through the ubiquitin 
proteasome pathway.  E6 also indirectly inhibits p53 function by interacting with 
p300/CBP which is a coactivator for p53 (Patel et al., 1999; Zimmermann et al., 
1999).  Absence of p53 function in the presence of DNA damage will prevent the 
cell from having enough time to repair the damage.  The cell cycle will go on with 
damaged DNA and this will lead to genomic instability. 
p53 activity is exerted through transcriptional regulation of proteins 
such as p21 cyclin-dependent kinase inhibitor (Levine, 1989) and Bax (Miyashita 
et al., 1994).  p21 can affect the cell cycle by arresting it in G1 and Bax is a pro-
apoptotic factor.  Though both mucosal high-risk and low-risk HPV E6 proteins 
bind p53, a significant difference is the fact that low-risk proteins do not target 
p53 for degradation (Li and Coffino, 1996).  In addition, not all cutaneous HPV E6 
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proteins bind p53 (Elbel et al., 1997).  A variety of behaviors regarding E6 and its 
action on p53 have been reported (binding of p53, targeting for degradation, 
ability to transform rodent cells) but there seems to be no correlation: the ability 
of E6 to transform rodent cells does not seem to depend on either its binding to 
p53 or its targeting for degradation of p53.  The question of why p53 is a target 
for E6 could then be addressed.  A possibility would be to prevent the cell from 
undergoing apoptosis or entry into senescence due to the action of E7, which will 
be discussed later. 
A second crucial activity for E6 is its ability to activate the telomerase 
ribonucleoprotein (Anderson et al., 1997; Klingelhutz et al., 1996).   
Telomerase is a reverse transcriptase whose minimal elements are the 
catalytic subunit hTERT and its associated RNA template hTER (Autexier et al., 
1996).  The limiting factor is the amount of hTERT.  It has been proposed that in 
association with c-myc, E6 is able to activate the transcription of hTERT 
(Veldman et al., 2001; Veldman et al., 2003), therefore increasing the global 
amount of telomerase ribonucleoproteins.  On the other hand, it has also been 
reported that E6 degrades myc and that telomerase’s activation by E6 is myc-
independent (Gewin and Galloway, 2001; Gross-Mesilaty et al., 1998).  The 
mechanism is still controversial but all reports do show an activation of 
telomerase by E6.   
Telomerase function is crucial for malignant progression.  Indeed, the 
end replication problem is a mechanism that prevents cells from undergoing too 
many replication cycles by shortening telomeres (mammalian linear chromosome 
ends) at each S-phase (Greider, 1990; Zakian et al., 1990).  If the telomeres get 
too short, the cells go into senescence or apoptosis.  Another function of 
telomeres is to prevent chromosome end-to-end fusion events through non-
homologous end-joining events.  Telomerase can extend telomeric DNA, thus 
preventing senescence and undesired non-homologous end joining.  A very large 
majority of cancers reactivate telomerase in order to maintain their proliferation 
potential (reviewed in (Satyanarayana et al., 2004)).  This feature is noticeably 
shared by stem cells that need to maintain their replication potential intact (Miura 
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et al., 2004).  Again, though telomerase activation is crucial for transformation, its 
significance in the view of the viral life cycle remains unclear. 
Another important class of binding partners for E6 is the PDZ family of 
proteins.  PDZ proteins contain a conserved domain that associates with the 
PSD-95, Dlg and ZO-1 proteins.  The PDZ domain is often found in proteins 
localized at areas of cell-cell contact, such as tight junctions in epithelial cells 
(reviewed in (Jelen et al., 2003)).  The binding of MUPP-1 (Lee et al., 2000b; 
Ullmer et al., 1998), hDLG (Kiyono et al., 1997; Lee et al., 1997), hSCRIB 
(Nakagawa and Huibregtse, 2000) to the extreme C-terminus of E6 results in the 
degradation of the PDZ proteins.  These interactions have been proven important 
for the progression of malignancies, as transgenic mice expressing high-risk E6 
lacking the PDZ domain but retaining the ability to degrade p53 fail to develop 
epidermal hyperplasia (Nguyen et al., 2003).  The signaling pathways involving 
these PDZ proteins often affect cellular adhesion, either cell-to-cell or cell-to-
extracellular matrix.  Unfortunately, these signaling pathways are not well 
defined; their dissection would be of great help in understanding the development 
of HPV-induced hyperplasias, hence pathogenesis. 
It has been possible to separate the effect of E6 on p53, on telomerase 
and the on PDZ-domain: it seems that the latter two are sufficient to immortalize 
cells, but that the first is necessary to fully transform cells (Longworth  and 
Laimins, 2004).  This conclusion suffers from cell-type variation and it appears 
that inactivation of Rb is often needed, either by mutation or through the activity 
of E7. 
Several other binding partners for E6 have been identified, such as 
paxillin (BPV (Tong and Howley, 1997), p300/CBP (Patel et al., 1999), E6-BP 
(Chen et al., 1995) or interferon regulatory factor 3 (IRF-3) (Ronco et al., 1998), 
but no function has yet been associated to these interactions.  All these activities 
clearly are not the primary role of E6 in the viral life cycle, but rather in the 
optimization of the cell context to permit viral genome amplification. 
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3.5.5. The E7 protein 
The E7 proteins of both high- and low-risk HPVs are about 100 amino 
acids in length.  It appears that E7 is important for both immortalization and viral 
pathogenesis.  Alone, this protein is able to immortalize NIH3T3 mouse cells and, 
poorly, human keratinocytes.  Efficient immortalization of keratinocytes requires 
the action of both E6 and E7.  Transgenic mice expressing E7 develop both low-
grade and high-grade cervical dysplasias that can progress to malignant lesions, 
while this is not the case for E6 (Munger et al., 1989a; Riley et al., 2003). 
The major feature of E7 is to bind to the Rb family of proteins (Dyson 
et al., 1989).  This interaction is mediated through one of three conserved 
regions in all high-risk E7 proteins: CR1 at the N-terminus, CR2 which contains 
the LXCXE motif that binds the Rb protein, and CR3 which contains two zinc 
finger-like motifs.  CR1 and CR2 domains have sequence homology to 
adenoviral E1A CR1 and CR2 domains that also bind to Rb proteins (Phelps et 
al., 1988).   
The Rb family of proteins is also known as “pocket” proteins and 
includes p107 and p130.  These proteins are differentially regulated throughout 
the cell cycle but the action of E7 is mainly the same on these proteins 
(Berezutskaya et al., 1997).  They will now be referred to as Rb unless otherwise 
indicated. 
The activity of the Rb protein depends almost exclusively on its 
phosphorylation state.  Unphosphorylated Rb binds to the E2F/DP1 transcription 
factors (Weintraub et al., 1995).  These factors would otherwise normally activate 
replication of cellular DNA.  Upon progression from the G1-phase to the S-phase, 
cyclin-kinase complexes phosphorylate Rb, releasing the E2F transcription 
factor, allowing production of proteins involved in DNA synthesis (Vernell et al., 
2003).  The interaction of E7 with Rb prevents the interaction of E2F with Rb, 
resulting in constant activation of the corresponding genes and therefore 
maintaining a cellular context in favor of DNA replication (Edmonds and 
Vousden, 1989).  Furthermore, the interaction of E7 with Rb eventually leads to 
its degradation through the ubiquitin proteasome pathway (Wang et al., 2001).   
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In the context of the differentiating epithelium, it is of importance to 
note that the Rb proteins are highly involved in the cell cycle exit as the 
keratinocyte begins to differentiate.  Therefore, the inactivation of these proteins 
by E7 allows productive replication in suprabasal differentiating keratinocytes 
(Cheng et al., 1995).   
The affinity of the binding of E7 to Rb depends on the virus: high risk 
E7s bind Rb with much higher affinity than low risk E7s, this difference is mainly 
due to sequence divergence in the CR2 domain (Ciccolini et al., 1994; Heck et 
al., 1992; Schmitt et al., 1994).  With a few exceptions (as HPV1), this affinity 
difference reflects the potential of E7s to induce lesions, as well as the severity of 
the lesions.   
E7 proteins also bind to cyclins A and E as well as to cyclin dependent 
kinase (cdk) inhibitors p21 and p27.  Since these proteins affect the 
phosphorylation state of Rb, it is not surprising E7 acts to increase the 
phosphorylation state of Rb (Davies et al., 1993; Funk et al., 1997; Jones et al., 
1997; Tommasino et al., 1993; Zerfass-Thome et al., 1996).   
Another group of proteins bound by E7 are the histone deacetylases 
(HDAC).  These proteins are also involved in the regulation of E2F target genes 
through remodeling of the chromatin, and the expression of the E2F target genes 
necessitates the concerted action of Rb to release E2F and HDAC to open the 
chromatin structure (Brehm et al., 1998; Weintraub et al., 1995).  In HPV-
negative cells, Rb binds HDACs and recruits them to E2F-inducible promoters.  
E7 binds HDACs independently of its interaction with Rb, but the binding of E7 to 
Rb or HDAC displaces HDAC from Rb (Brehm et al., 1998; reviewed in 
Longworth and Laimins, 2004).  It has also been shown that this interaction is 
important for the episomal maintenance of the viral genome as well as for 
immortalization of the cell (Longworth and Laimins, 2004).  Apart from their 
action on nucleosomes, HDACs can also inactivate E2F factors by deacetylation 
(Marks et al., 2001).  The action of Rb and HDAC seem both to prevent the 
activation of E2F target genes.  It is therefore not surprising that E7 must act on 
both proteins in order to activate the expression of E2F target genes. 
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3.5.6. The L1 protein 
The capsid of HPV viral particles is made of two proteins: L1 and L2.  
The first is found in a large majority and is sufficient to form virus-like particles 
(VLPs) (Giroglou et al., 2001; Pinto et al., 2003).  The 55 nm diameter 
icosahedral capsid consists of 72 capsomeres, is quite stable and resistant to 
heat treatment (Bonnez et al., 1994; Bonnez et al., 1993).  L1 is a 55kDa protein, 
and L1 units interact through their C-terminal domain (Chen et al., 2000).  
Controversial studies suggest a role in the cellular uptake of viral particles 
through interaction with the integrin heterodimer α6β4 (Yoon et al., 2001).  This 
heterodimer is found mainly on the cell surface of keratinocytes of the basal layer 
of the stratified epithelium; hence, the current model of HPV infections occurring 
through micro-lesions of the stratified epithelium, giving access to the basal layer 
of cells. 
Interaction of intact assemblies of HPV L1 with heparan sulfate 
proteoglycans has been reported to be found within the extracellular matrix 
(Rommel et al., 2005). 
As L1 is the major protein forming viral capsids, it has been the main 
target in developing vaccines (Brown et al., 2004; Harper et al., 2004).  
Correlations between high anti-L1 antibody titers and regression of high-risk HPV 
positive mild/moderate dysplasia have been reported (Griesser et al., 2004). 
Once the virus has entered the cell, it must travel to the nucleus in 
order to express its genes and replicate its DNA.  Interactions of L1 with nuclear 
import factors have suggested the viral particle is targeted to the nucleus as an 
intact virion (Nelson et al., 2002; Nelson et al., 2003).  However, this would be in 
contradiction with reported confocal microscopy experiments regarding the 
localization of L2 and packaged DNA in HeLa cells suggesting the viral particles 
are uncoated in the cytoplasm rather than in the nucleus (Day et al., 2004). 
The fact that L1 can form VLPs does not exclude L2 from the capsid.  
In fact, it has not been possible to package viral mini-chromosomes using only L1 
as capsid protein.  L1 has also been shown to interact with L2 (Finnen et al., 
2003). 
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3.5.7. The L2 protein 
The capsid is mainly composed of the major L1 protein, but for the 
production of functional viral particles the L2 minor protein must also be present.  
The L2 protein, the second component of the capsid, is about 70-75 kDa in size, 
and is expressed in the same terminally differentiating cells as L1 (Doorbar and 
Gallimore, 1987; Trus et al., 1997). 
L2 is essential to form infectious and replication-competent viral 
particles (Roden et al., 1996; Stauffer et al., 1998).  It has been proposed that L2 
interacts with the viral genome and with L1, allowing packaging in the newly 
made viral particle of the viral episome (El Mehdaoui et al., 2000; Mallon et al., 
1987; Zhou et al., 1994).  Once the viral particle has entered the cell, it has been 
suggested that L2’s interaction with β-actin might participate in the transport of 
viral particles to the nucleus (Yang et al., 2003).  Similarly, a reported interaction 
with microtubules might allow dynein, a motor protein, to transport either infecting 
particles or newly made viral particles (Florin et al., 2002). 
Some vaccination studies suggest immunization with L2 proteins may 
provide immunity to a broader range of HPVs than immunization with L1-VLPs, 
due to more conserved sequences (Roden and Wu, 2003).   
 
 
3.6. The E4 gene and gene product 
 
The E4 ORF is found within that of E2.  It is expressed as a fusion 
protein of the five first amino acids of E1 spliced to the E4 ORF (Chow et al., 
1987).  Therefore, it is often referred to as E1^E4.  In this report, it will always be 
referred to as E4. 
The expression pattern of HPV E4 varies from one HPV type to 
another (Middleton et al., 2003).  But in most cases, when expressed, the 
transcript and the protein are found in very high amounts. 
In the current model of the HPV16 life cycle, the E4 protein is found 
predominantly in the upper layers of the stratified epithelium (Fig. 4).  The mRNA 
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encoding E4 is the most abundant (Bohm et al., 1993; Grassmann et al., 1996) 
and it has been proposed that the HPV1 E4 protein can account for up to 20-25% 
of the cell’s total protein content (Breitburd et al., 1987; Doorbar et al., 1986).  It 
is currently often hypothesized that E4 might be present in earlier stages of the 
viral life cycle, but the amounts would not be as readily detectable.   
A differentiation-inducible promoter found within the E7 ORF has been 
suggested to drive the transcription of an mRNA having the coding potential for 
E4 (as well as for E5) (Grassmann et al., 1996), perhaps increasing the amount 
of E4 found in the upper layers of the stratified epithelium. 
The cutaneous HPV E4 proteins are poorly conserved among HPV 
types but maintain partial physical characteristics (Doorbar et al., 1989).  
However, the homology between cutaneous and mucosal HPV E4 proteins is 
quite low.  The lengths vary from 74 amino acids to over 300.  This variation 
alone suffices to emphasize that the results obtained for one of the E4 proteins 
cannot always be extrapolated to the E4 protein of another HPV type. 
HPV16 E4 is 92 amino acids long; various activities have been 
assigned to domains of the peptide (Fig. 5).  One of the earliest and most striking 
observation is that E4 can colocalize to and reorganize the cytokeratin network in 
keratinocytes (Doorbar et al., 1991).  This observation was made in cultured 
cells, but in vivo analysis of low-grade lesions reveals a fraction of infected cells 
reacting in a similar manner to the presence of high amounts of E4 (Wang et al., 
2004).  The discrepancy between the cultured cells and in vivo data concerning 
the collapse prevalence might be due to the fact that the collapse of cytokeratins 
could modify the adhesive properties of the cell in vivo, hence these cells could 
be lost, either in the process of analysis or before the sample arrives in the 
laboratory. 
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Though extensive studies have been made, the function of E4 in the 
viral life cycle remains unclear.  The most significant observation regarding the 
cytokeratin network reorganization and the rather late high expression of E4 
suggests a role in virus release.  But because of the difficulty in growing HPV16 
virus particles in the laboratory, there is no experimental evidence supporting this 
hypothesis yet.  It has also been proposed that E4 might have a function in the 
vegetative amplification of the viral episome, in view of the synchrony of the DNA 
amplification and E4 expression.  For the same reasons as mentioned above, 
only little experimental evidence supports this hypothesis.  However, the use of 
cottontail rabbit papillomavirus knock-outs for E4 showed that genome 
amplification is reduced in the absence of E4 (Peh et al., 2004).   
In vitro data has shown that E4 is able to block the cell cycle in the G2 
phase, in mammalian cells as well as in yeast cells (Davy et al., 2002).  The fact 
that the cell cycle block can affect such organisms suggests that E4’s action 
takes place on well-conserved pathways throughout evolution.  Indeed, close 
analysis of the “G2-arrest” domain (amino acids 17-45) shows several interesting 
features: within the proline-rich region a putative cdk consensus phosphorylation 
Keratin reorganization and self-
association domain 
Fig. 5 : Representation of E4 showing the E1 portion (red), the leucine-rich region 
(yellow) and various domains associated with observed properties of E4. 
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site is found, a putative nuclear localization signal (NLS) is found as well as a 
putative cyclin binding motif.  On top of these features, several serine residues 
are located in the “G2-arrest” domain, which can constitute phosphorylation sites.  
This G2-arrest activity could also justify why there is a selection against E4 
during the development of malignant lesions. 
It should be kept in mind that such effects on the cell probably do not 
require the surprisingly high amount of E4 which is detected in the upper layers 
of low-grade lesions.  Perhaps this arrest could be exerted in cells in which the 
amount of E4 has not yet reached such levels, such as basal or spinous cells. 
Unless the distribution of E4 prevents cyclins, for example, from entering the 
nucleus and allowing the cell to continue its cycle, the pattern in which E4 is seen 
in the late stages of the viral life cycle may not represent the state of E4 needed 
to arrest the cell cycle.   
It also has been reported that E4 binds a potential RNA helicase 
through its C-terminus domain.  Moreover, it appears that the interaction affects 
the ATPase activity of the helicase (Doorbar et al., 2000).  The specific 
association of this helicase with E4 could suggest a role for E4 in the viral life 
cycle.  To date, there is no evidence supporting a possible effect of this helicase 
on the amounts or patterns of the various viral mRNAs in the late stages of the 
viral life cycle.  Nevertheless, as late genes must be expressed in order to 
produce capsid proteins and assemble viral particles, perhaps an E4-associated 
RNA helicase could exert such an activity.   
The strikingly high amount of E4 tends to suggest a more structural 
function for E4.  In addition, the reorganization of the cytokeratin network due to 
E4 in the upper layers of the epithelium where viral particles are assembled hints 
at a potential effect on the cell’s mechanical properties.  To address this 
question, part of this work used atomic force microscopy to analyze the direct 
effect of E4 on the cell’s mechanical properties.   
When cells lacking cytokeratins express E4, the observed pattern is a 
more punctate cytoplasmic staining.  It has been reported that the structures to 
which E4 is localized are mitochondria (Raj et al., 2004).  The same study also 
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shows that once E4 has reorganized the cytokeratin network of keratinocytes, it 
re-localizes to mitochondria, reorganizes them in a manner similar to the 
cytokeratin network and diminishes the inter-membrane electrical potential of the 
mitochondria.  Speculations on such a behavior suggest that clustering 
mitochondria near the nucleus might be a means of concentrating ATP close to 
where viral DNA replication occurs.  Nevertheless, no evidence supports this 
model yet.  In addition, from the viral life cycle point of view, the timing seems to 
be somewhat inconsistent.  Indeed, in vivo low-grade lesions seldom show 
cytokeratin collapse.  If E4 were to collapse cytokeratins perhaps to modify the 
cell’s mechanical properties, to dissociate from the cytokeratins, go to 
mitochondria and reorganize them in order to optimize the occurrence of viral 
DNA replication, one would expect to see collapsed cytokeratins or punctate 
mitochondrial patterns of E4 with a higher frequency.  Though it has not been 
shown that these events must be sequential, a simultaneous effect of E4 on the 
cytokeratin network and on the mitochondria hasn’t been reported and, according 
to in vivo data, seems rather unlikely. 
 During this work, E4 has shown to be a difficult protein to work with.  
Indeed, the HPV16 E4 protein does not behave in a very constant way.  
Transfection efficiencies vary, the use of GFP reporter constructs seldom is 
representative of how E4 will behave and recombinant viral approaches do not 
often succeed.  Moreover, the design of an inducible cell line has proven 
challenging. 
 
 
3.7. Epithelium 
 
Epithelia are tissues (also considered to be organs in some cases) that 
serve as protection and a barrier for organs and individuals.  Their main roles are 
to prevent  desiccation (Attenborough, 1980) as well as to maintain physical 
integrity.  
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There are several types of epithelia: simple, cuboid, stratified, 
pseudostratified, cutaneous and mucosal.  The most common one is the skin, 
which is a cutaneous stratified epithelium and has a surface of nearly 2 m2, 
depending on the individual.  All epithelia lie on a basal lamina, which is secreted 
by the cells of the basal layer.  It provides structural support and acts in part as a 
selective barrier for the epithelial layer (Erickson and Couchman, 2000; Kalluri, 
2003; Timpl and Brown, 1996) and reviewed in (Sasaki et al., 2004).  As seen by 
electron microscopy, the basal lamina is formed by an electron-dense layer 50-
80 nm thick, composed of non-fibrous type IV collagen and heparan sulfate, 
surrounded on both sides by a less dense layer containing laminin.  This basal 
lamina is not exclusively associated with epithelium but is also found in 
endothelia and other cell types. 
The epithelium is avascular, the blood vessels underlying the basal 
lamina supply the necessary nutrients and evacuate the metabolites which are 
transported to and from the epithelial cells by diffusion through the basement 
membrane (Oldfors and Fardeau, 1983).   
As epithelia are the sites of contact between the inner compartment of 
the individual and the environment, they are subjected to many hazards.  The 
loss of cells is important, not only by normal shedding but also by friction, cuts, 
mechanical damage, and destruction of the cells.  Therefore, the epithelium must 
have a high rate of renewal.  As their proliferation is significant, epithelia are 
tissues from which a large number of cancers can originate (adenocarcinomas) 
(Owens and Watt, 2003). 
The niche for HPV is stratified epithelium.  The different HPV types will 
infect either cutaneous or mucosal stratified epithelium.  HPV16 infects the 
mucosal stratified epithelium of the cervix.   
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3.8. Epithelial Differentiation 
 
As mentioned in the previous paragraph, HPV16 infects stratified 
mucosal epithelium.  The life cycle of the virus is tightly linked to this form of 
epithelium, as the stratification of the epithelium is accomplished through 
differentiation of basal layer cells.  This differentiation is paralleled with the 
migration of the cells towards the lumen of the cervix.  If viral DNA is in such a 
cell, the life cycle can begin. 
The differentiation process is a complex cascade of regulatory events.  
A major hallmark is mutual exclusion of mitosis and differentiation; as soon as a 
basal cell leaves the basal lamina and has triggered its differentiation, it has only 
a small potential for proliferation, about 30 divisions.  It then belongs to the transit 
amplifying pool of cells (Watt, 2002b).  Hence, epithelial stem cells do not 
undergo rapid and continuous division cycles, even though they have the 
potential to do so.  Cells that further leave the transit amplifying pool pursue the 
differentiation program and exit the cell cycle.  Importantly, differentiation is 
thought to be a non-reversible process though reports suggest HPV E7 can 
reactivate cellular DNA replication in non-cycling differentiating cells (Cheng et 
al., 1995). 
The detailed mechanism and regulatory events involved in epithelial 
differentiation are not fully understood.  Nevertheless, a series of markers have 
been identified to distinguish different stages of the differentiation process (Fig. 6, 
reviewed in Nemes and Steinert, 1999). 
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The regulatory processes described to date all seem to show a 
transient increase in p21 in order to trigger the differentiation process and 
possibly to escape the cell cycle (Di Cunto et al., 1998).  The role of the 
serine/threonine kinases ROCKI/II (signal mediators of RhoA) has proven to be 
critical in the decision of a daughter basal keratinocyte either to trigger the 
differentiation pathway or to remain in the basal layer and continue proliferation 
(McMullan et al., 2003).  Inhibition of ROCK has been reported to prevent 
keratinocyte terminal differentiation and increase proliferation, whereas ROCK-II 
activation arrests the cell cycle and increases the expression of differentiation 
markers such as involucrin and transglutaminase-I.   
The underlying stromal cells have been reported to influence partially 
the outcome of the differentiating epithelium (Okazaki, 2003).  Between the 
underlying stromal cells and the basal cells lies the basal lamina.  Adhesion of 
the basal cells to the basal lamina is not merely a mechanistic property, it also 
signals to the cell.  Specific adhesion of basal keratinocytes to the basal lamina 
occurs through integrin heterodimers.  The α6β4 integrin heterodimer is found 
specifically at this interface and binds the laminin of the basal lamina.  It has 
been suggested that disruption of adhesion through the α6β4 integrins 
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Granular layer 
Cornified layer 
Fibroblast 
Fig. 6 : Markers for the different stages of the stratified epithelium differentiation process. 
p63, K5, K14 
K1, K10, Involucrin, Transglutaminase-I 
Loricrin, Profilaggrin, SPR1/SPR2 
Filaggrin 
 33
constitutes of itself a signal sufficient to begin differentiation (Green, 1977; 
Owens et al., 2003). 
Another crucial factor involved in the fate of a basal keratinocyte is 
p63.  In its absence, the normally stratified epithelium remains single-layered 
(Koster and Roop, 2004).  In the same way, when expressed in a single-layered 
epithelium, a stratification program is initiated (Koster et al., 2004).  
Nevertheless, its molecular role remains controversial. 
The Notch family of receptors has also been reported to be involved in 
the fate of epithelial stem cells.  When activated by Jagged-1, Notch-1 activates 
the NFκB and PPARγ pathway which in turn leads to full differentiation of 
keratinocytes (Nickoloff et al., 2002).  Activation of Notch-1 by Delta-1 has also 
been reported to trigger epithelial differentiation in low concentrations (as at the 
upper border of the stem cell compartment), whereas high concentrations seem 
to favor a stem cell phenotype (Lowell et al., 2000). 
A number of years ago, it was reported that the expression of various 
keratins is not only correlated with stratification but more specifically with 
differentiation per se (Byrne et al., 1994).  The stratification of the epidermis 
seems to be the result of several, sometimes unrelated, molecular regulators, as 
the above-mentioned p63 or Notch-1 receptor. 
A number of other factors have been reported to regulate keratinocyte 
differentiation.  Calcium is a commonly used means of in vitro keratinocyte 
differentiation (Bikle et al., 2001; Deucher et al., 2002), but vitamin A (Poumay et 
al., 1999), protein kinase C activators (Welter et al., 1995) and antioxidants 
(Balasubramanian et al., 2002) have also been suggested to enhance 
keratinocyte differentiation. 
The differentiation process seems to involve a number of pathways, 
some certainly having aspects redundant with others.  This complexity possibly 
underlines the crucial necessity of a correctly ordered differentiation process for 
the integrity of the organism. 
 
 
 34
3.9. Atomic Force Microscopy 
 
As alluded to above, in addition to more familiar methods, atomic force 
microscopy (AFM) was used in this study.  It will therefore be briefly described 
here.  AFM was first engineered in 1986 by Binnig, Quate and Gerber and is a 
function of the scanning probe microscope, measuring attractive and repulsive 
forces between a tip and the sample surface with very high resolution (lateral 
resolution: ~10Å, vertical resolution <1Å) (Binnig et al., 1986). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The detector 
The laser beam 
The cantilever and its 
probe (tip) 
The sample 
The piezo-electric 
crystal 
Fig. 7 : The essential elements of the AFM: the piezo-electric crystal is moved while the 
probe scans the surface of the sample.  The cantilever is deflected an amount which 
depends on the force of the interaction with the sample.  A detector measures the 
deflection of the cantilever by means of a laser beam reflected on the top of the cantilever. 
(adapted from http://www.mih.unibas.ch/Booklet/Booklet96/Chapter3/Chapter3.html) 
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Initially, the microscope was used in vacuum chambers and the 
sample’s mechanical properties were hard enough so the tip would measure its 
exact topology.  Inorganic crystals were often used, followed by crystallized 
proteins (Fig 8).  The sample-to-tip interface is not true contact, due to repulsive 
and attractive electrical forces (Fig. 9).  AFM then evolved and was adapted to 
measurements in liquid and finally on live biological samples (Ando et al., 2003; 
Lehenkari et al., 2000). 
The data acquired by AFM on biological samples are presented as a 
force-curve (Fig. 10).  The information each curve contains is then processed 
through computerized custom software to obtain the local topology and 
mechanical properties of the sample.  Fig. 11 gives an example of the type of 
results obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8: Images of crystallized connexons in their “open” configuration (left panel) or in their 
“closed” configuration (right panel).  The resolution of the AFM measured the opening of 
the channel to vary from 0.6 + 0.3 nm (closed) to 1.5 + 0.3 nm (open). (adapted from 
http://mcdb.colorado.edu/courses/3280/lectures/class04.html) 
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Fig. 9 : The electrical repulsive and attractive forces depend on the distance from tip to 
sample. (adapted from http://mcdb.colorado.edu/courses/3280/lectures/class04.html) 
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There are a number of technical problems in analyzing live cells that 
need to be solved.  In the particular case of our work, in addition to temperature, 
CO2 concentration and pH of the media, one has to be sure that the scanned cell 
expresses E4 and the cells must not be confluent (a confluency of about 20-30% 
is needed). 
 
 
 
 
 
 
 
 
 
 
 
 
The AFM used is mounted on an inverted optical microscope and is 
equipped with fluorescent light.  This configuration allows the user to find cells 
with fluorescence in the FITC-GFP-Alexa 488 emission spectrum. 
The user can choose the size of the scanning area and the number of 
probing events (definition of the image / pixels).  In all experiments presented 
here, the scanning size was 10µm x 10µm and the definition was 32 x 32 probing 
events. 
 
 
 
 
 
Fig. 11 : Example of results obtained with 
the AFM.  A HeLa cell pseudopod was 
scanned and the acquired data was 
processed.  The topology is real and the 
color code represents the local rigidity of 
the sample (blue: hard, red: soft).  The gray 
area is the culture support and serves as 
reference.  Each pixel of the image is 
obtained with one force curve. 
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4. Aim of the Project 
 
Cervical cancers are thought to appear due to infection by the human 
papillomavirus type 16 (HPV16).  Among the viral proteins encoded by HPV16, 
the E4 protein is of particular interest.  As it is made in high amounts in the late 
stages of the viral lytic cycle, it is likely to have a significant role.  However, this 
function remains to be determined. 
In a normal infection, the virus usually does not trigger malignant 
transformation of the infected cell; it appears that induction of cancer requires the 
accidental disruption and integration of the viral genome into the host cell’s 
chromosomes.  In this context, the E4 gene is generally not expressed, leading 
to the absence of the E4 protein in transformed cells.  It is not clear yet why the 
E4 protein seems to be selected against in cells progressing to malignancy. 
Very little is known on the function of the E4 protein in the viral life 
cycle nor why the E4 protein is generally absent in transformed cells.  I therefore 
studied the properties of E4 to try and elucidate further the function of the E4 
protein in the viral life cycle of HPV16.  This was achieved by using familiar 
methods as well as less familiar methods. 
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5. Materials and Methods 
 
5.1. Cloning 
The major cloning vector used is pMV11 which is a pUC18 based 
vector with the minimal enhanced CMV promoter driving the expression of the 
transgene.  The E4 cDNA was cloned as a BamHI-EcoRI fragment.  The 
enhanced green fluorescent protein (eGFP) was amplified using PCR and the 
following primers: BamHIeGFP 5’-
ACGTGGATCCATGGTGAGCAAGGGCGAGGAG-3’; eGFPEcoRI 5’-
ACGTGAATTCTTAACCCTCACTAAAGGGAAGCGC-3’(all primers were ordered 
at MWG-Biotech).  The PCR fragment and the pMV11 were then digested with 
the BamHI and EcoRI restriction enzymes (all restriction enzymes used are from 
Roche) and ligated together.  The ligation product was then electroporated into 
DH10β E. coli cells.  Colonies were then amplified and selected by miniprep 
culture supplemented with the appropriate antibiotic, DNA extraction (Eppendorf) 
and digestion with BamHI and EcoRI restriction enzymes.  2 Positive clones were 
then chosen and amplified by midiprep culture supplemented with the 
appropriate antibiotic and DNA extraction (Promega Wizard kit) according to 
manufacturer’s instructions giving rise to the pMV11eGFP plasmid. 
The pMV11zeo plasmid was obtained in the same manner using the 
primers BamHI_zeo_fw 5’-CTAGGGATCCATGGCCAAGTTGACCAGTGCCG-3’ 
and zeo_EcoRI_rv 5’-GAACGAATTCTCAGTCCTGCTCCTGGCCCAC-3’.   
The TAT-E4 fusion protein was obtained by cloning E4 in the pTAT 
vector (kindly provided by Dr. Dowdy) by amplifying the E4 fragment using the 
PCR reaction and the following primers: 5XhoIE4 5’-
GGTTCTCGAGATGGCTGATCCTGCAGCAGCAAC-3’ and 3EcoRIE4 5’-
CATGGAATTCCTATGGGTGTAGTGTTAC-3’.  The PCR fragment and the pTAT 
vector were then digested with the XhoI and EcoRI restriction enzymes, ligated 
and electroporated into DH10β E. coli cells.  Mini-cultures and DNA extraction 
was then performed and digestion with XhoI and EcoRI was used to select 
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positive clones.  2 clones were then amplified by midiprep culture and DNA 
extraction following the manufacturer’s instructions (Promega Wizard).   
In order to try and obtain lentiviruses expressing E4 under the control 
of the EF1α promoter, a third generation system was used, including vectors 
pRDI-282 (backbone), pRDI-275 (helper) and pAD-3 (helper) (all vectors kindly 
provided by the Iggo lab).   
The backbone vector pRDI-282 also contains the IRES followed by the 
eGFP cDNA and was used as such. 
In order to obtain a stable cell line expressing E4 upon induction, the 
S2.10HeLa cell line containing the Tet-on inducible VP16 element was used 
(kindly provided by the Lingner lab) and the E4 cDNA was cloned in BamHI / ClaI 
of the pTRE2-pur plasmid (Clontech).   
 
5.2. Cell Lines, culture conditions and chemicals used 
HeLa (ATCC n° CCL-2.2) was the main cell line used.  U2OS (ATCC 
n° HTB-96), Saos-2 (ATCC n° HTB-85) and 293T (CRL-11268) were also used.  
These four cell lines were grown at 37°C, 5% CO2, in Dulbecco’s Modified Eagle 
Medium (DMEM) (Gibco) supplemented with 10% heat-inactivated fetal calf 
serum (FCS) (Brunschwig) containing 50 U/ml penicillin (Gibco) and 50 µg/ml 
streptomycin (Gibco) unless specified.   
For affecting the distribution of the microtubule and actin networks, the 
following chemicals were used: nocodazole (Sigma) and cytochalasin D (Sigma), 
respectively, at the indicated concentrations and for the indicated amounts of 
time.   
 
5.3. Transfection methods 
50 µl of Lipofectamine 2000 (Invitrogen) and 20µg of DNA were used 
to transfect each 10 cm dish of HeLa, U2OS and Saos-2 cells at a density of 90-
95% according to the manufacturer’s instructions.  For the lentivirus production, 
293T cells were transfected using the calcium phosphate method (Graham and 
van der Eb, 1973). 
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For cells destined for AFM analysis, a confluent 10 cm dish of HeLa 
cells were harvested by trypsinization and collected in 2ml of DMEM without 
FCS.  Appropriate amounts of Lipofectamine 2000 and DNA prepared following 
the manufacturer’s instructions were added.  The cells and DNA were then 
incubated on sterile bacterial culture dishes in an incubator (37°C, 5% CO2) for 
90’.  Cells were then seeded at the desired density in dishes previously coated 
for a minimum of 20’ at 37°C with coating solution (1 mg human fibronectin 
(Sigma), 3.2 mg type I bovine collagen (Vitrogen) and 10 mg bovine serum 
albumin (Biofluid) in 100 ml DMEM) with or without glass coverslips.   
 
5.4. Electroporation 
a)  Bacteria 
50µl of electro-competent bacteria were mixed with the appropriate 
amount of DNA and transferred to an electroporation cuvette (BioRad) with a 
1mm gap.  Electroporation was performed with the BioRad Gene Pulser II 
electroporator with the following settings: 1800V, 25µF and 200Ω (empty cuvette 
should give a time constant close to 4.5-5.0 msec).  The bacteria were then 
collected, diluted in 950µl SOC medium (0.5% Yeast extract, 2% Bacto Tryptone, 
10mM NaCl, 2.5mM KCl, 20mM Glucose and 10mM MgCl2) and incubated 30’ at 
37°C shaking.  The bacteria were then plated over night on LB agar containing 
the appropriate antibiotic. 
b)    Mammalian cells 
20 hours prior to electroporation, sub-logarithmic cells were grown in 
RPMI 1640 (Gibco) supplemented with 10mM dextrose (D-Glucose) and 0.1mM 
dithiothreitol (DTT, Sigma) and antibiotics. 
The cells were harvested by trypsinization and washed twice with 
phosphate buffered saline (PBS) and diluted to 14.2 x106 cells / ml in 
supplemented RPMI 1640.  10-15µg of DNA were added to 300µl of cells and 
transferred to a 4mm-gap electroporation cuvette (BioRad).  The settings were as 
follows: 300V, 500µF, resistance at maximum (empty cuvette should give a time 
constant in the 25-35 msec range). 
 42
The cells were then collected and grown in DMEM supplemented with 
10% FCS and antibiotics and seeded on plates previously coated 20’ at 37°C 
with coating solution. 
 
5.5. Protein Extraction 
The cells growing in a dish were washed twice with PBS and harvested 
using a rubber policeman.  Extraction from the pelleted cells was performed 
using water diluted reporter lysis buffer (RLB, Promega), a cocktail of protease 
inhibitors (Calbiochem) and 30’ incubation on ice.  The lysat was then centrifuged 
5’ at 10’000g.  The soluble supernatant was collected, the pellet was suspended 
in 8M urea and incubated 3 hours at 37°C.  Following incubation, the sample was 
centrifuged 15’ at 10’000g and the supernatant collected (insoluble fraction).  The 
protein concentration was measured by Bradford (BioRad) staining. 
 
5.6. Fusion protein production and purification 
In order to produce TAT-E4 proteins, BL21 (DE3) pLysS bacteria 
(Novagen) were transformed with pTAT-E4 or pTAT constructs.  A 5ml 2xYT 
miniculture was grown 8hours shaking at 37°C and then transferred into 500ml 
2xYT and grown over night at 37°C, shaking (all cultures are done in the 
presence of the appropriate antibiotic).  The following morning, isopropyl-β-D-
thiogalactosid (IPTG) was added to 300 µM during 6 hours.  The bacteria were 
then harvested by centrifugation, washed with PBS and pelleted.  The pellet was 
then resuspended in 25 ml buffer Z (8M urea, 100mM NaCl, 20mM HEPES pH 
8.0).  The bacteria were then lysed by 8 pulses of 10 seconds of sonication on 
ice.  The lysat was then centrifuged 15’ at 14’000 rpm, at 4°C.  To the 
supernatant, 1 ml of pre-equilibrated Ni-NTA agarose beads (Qiagen) were 
added.  To the supernatant and beads solution, imidazole is added to 50mM.  
Over night incubation at 4°C, rotating, allows the fusion protein to bind to the 
beads.  The next morning, the beads are pelleted by centrifugation 5’ at 2’000 
rpm, at 4°C: the supernatant is the flowthrough.  The proteins are eluted off the 
beads with 2ml buffer Z supplemented to 1M imidazole for 15’ at room 
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temperature or over night at 4°C.  To collect the eluate, centrifugation 5’ at 2’000 
rpm, at 4°C was performed.  The eluate was further desalted using PD-10 
columns (Amersham Biosciences) pre-equilibrated with 5x 5ml of PBS.  Fractions 
containing the proteins are then collected, aliquoted and frozen.  Protein content 
is then assessed by Bradford staining.   
If dialysis was performed, a 1.5ml cassette (Slide-a-Lyzer, Pierce) was 
used over night in 1000ml of the target buffer. 
 
5.7. Western blotting and antibodies used 
Quantified protein extracts were resolved by migration through a 
sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) whose 
concentration depended on the target protein(s).  The samples were then 
transferred to a poly(vinylidene fluoride) (PVDF) membrane (0.45µm, Immobilon, 
Millipore) by electrophoresis.  The membrane was then blocked 60’ at room 
temperature in PBS containing 5% milk (Rapilait).  Following three washes with 
PBS, the membrane was further incubated 60-120’ at room temperature in PBS 
containing 5% milk and the appropriate antibody to the indicated dilution. 
Three washes were then performed and the membrane was then 
incubated 30-60’ at room temperature in PBS containing 5% milk and the 
appropriate secondary antibody coupled to horse radish peroxidase.  Finally, 
three PBS washes were followed by 1’ incubation with the enhanced 
chemiluminescent reagent (Amersham Biosciences) and exposure on a film. 
The antibodies used are the following: α-E4 TVG402 (kind gift from J. 
Doorbar), α-Cytochrome C (Santa Cruz), α-Caspase 3 (Becton Dickinson), 
Involucrin (NeoMarkers, clone SY5), α-actin (Santa Cruz); secondary antibodies: 
HRP-α-mouse and HRP-α-rabbit (Jackson Laboratories). 
 
5.8. Mitochondria Extraction 
In order to extract mitochondria, HeLa cells were harvested in PBS 
with a rubber policeman.  The cells were pelleted and the supernatant was 
discarded.  The pellet was resuspended in 10mM phosphate buffer pH7.2 and 
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250mM sucrose at 4°C.  The cells are the transferred to a Dounce homogenizer 
and subjected to 15 strokes at 4°C.  The homogenate was then centrifuged 10’ at 
350g, at 4°C.  The supernatant was then transferred to a new tube and 
centrifuged 10’ at 500g, at 4°C.  The supernatant was again transferred to a new 
tube 10’ at 650g, at 4°C.  Finally, the supernatant was once again transferred to 
an Ultra-Clear 5ml tube. 1-1.5ml of phosphate buffer were added and the tube 
was then filled with liquid paraffin.  Centrifugation 20’ at 12’000 rpm, at 4°C was 
performed.  The pellet should contain enriched mitochondria and is resuspended 
in PBS. 
 
5.9. Immunofluorescence 
Immunofluorescence experiments were carried out with cells grown on 
glass coverslips.  The coverslips were collected and washed twice with PBS.  
The cells were then fixed 15’ at room temperature with 5% formalin in PBS.  
Three washes with PBS were followed by a 60’ incubation at room temperature 
with 0.5% NP-40 (Sigma), 5% milk and 1% FCS in PBS to block and 
permeabilize the cells.  The following incubation was done with the appropriate 
primary antibody diluted in PBS containing 5% milk and 1% FCS at room 
temperature for 60’.  Another three PBS washes were followed with a 60’ 
incubation at room temperature with PBS containing 5% milk, 1% FCS and the 
appropriate secondary antibody.  Finally, three washes with PBS were followed 
with a 1’ incubation at room temperature with 4’, 6-diamidino-2-phenylindole 
dihydrochloride (DAPI, Sigma) diluted in water.  Two washes with water were 
done before mounting the coverslips in 30% 1, 4-diazabicyclo-(2, 2, 2)-octane 
(DABCO, Sigma) – 70% glycerol on glass slides and sealed with nail polish.  
Dilutions used for the antibodies were as follows: TVG402 α-E4 1:5, all other 
primary antibodies were used at a 1:200 dilution whereas secondary antibodies 
were used at a 1:1000 dilution.  Antibody origin: α-E4 (TVG402) was a kind gift 
from J. Doorbar, α-microtubules (β-tubulin): NeoMarkers, α-cytokeratins: Santa 
Cruz, Alexa488-α-mouse: Molecular Probes, Alexa488-α-rabbit: Molecular 
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Probes, Cy3-α-mouse: Jackson Laboratories, Cy3-α-rabbit: Jackson 
Laboratories. 
 
5.10. Reverse Transcription and Real-Time Polymerase        
Chain Reaction (RT-PCR) 
Total RNA from growing cells was extracted using the RNeasy kit 
(Qiagen) according to the manufacturer’s instructions and quantified using 
spectrophotometry.  4µg of RNA was then treated with RNase-free DNaseI 
(Roche) in 200mM MgCl2, 100mM DTT, 200mM Tris pH 8.0 (Sigma) in presence 
of 4U RNase inhibitor (Protector, Roche) for 60’ at 37°C to prevent contamination 
with cellular DNA. 
Random reverse transcription was then performed with 1µg of DNaseI 
treated RNA by first denaturation 10’ at 70°C in the presence of 1µM random 
hexanucleotides (Invitrogen) in a final volume of 11µl followed by 5’ chilling on 
ice.  Addition of 4µl of 5x enzyme buffer, 2µl of 100mM DTT, 1µl 10mM ultrapure 
dNTPs (Amersham Biosciences), 4U Protector RNase inhibitor and 100U M-MLV 
reverse transcriptase (Gibco) to a final volume of 20µl preceded 60’ incubation at 
42°C.  Inactivation of the enzyme was performed by heating the samples 15’ at 
70°C. 
The quantitative PCR reaction was performed using the SYBRGreen 
Applied Biosciences kit.  For each sample, 10% of the reverse transcription 
reaction were used.  Addition of 12.5µl of 2x reaction buffer, primers to 400nM 
and water to 25µl preceded the PCR reaction.  The following primers were 
designed using the Primer Express 1.0 software: for E4 fw: 
AGCGACCAAGATCAGAGCCA and rv: GTGAGGATTGGAGCACTGTCC; for 
zeocin fw: GAGTGGTCGGAGGTCGTGTC and rv: CGAACTCCCGCCCCC; for 
involucrin fw: AAGACTGTTCCTCCTCCAGTCAA and rv: 
GCTCGACAGGCACCTTCTG; for GAPDH fw: GTATTCCCCCAGGTTTACAT 
and rv: TTCTGTCTTCCACTCACTCC.  PCR reactions were carried out in a 
PE5700 PCR machine (Perkin Elmer) performing the following program: 2’ at 
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90°C followed by 40 cycles of 30’’ at 90°C, 30’’ at 60°C and ended by indefinite 
time at 4°C. 
 
5.11. FACS analysis 
In order to evaluate the amount of free cytoplasmic Ca2+, FACS 
analysis was performed.  Treated or untreated cells were incubated 30’ at 37°C 
with 10µM Indo-1 (Molecular Probes).  The live cells were harvested by 
trypsinization or centrifugation depending on their adhesion status and then 
subjected to FACS analysis using the Becton Dickinson LSR apparatus.  It is 
important to maintain the cells at 37°C as Ca2+ increases in response to 
temperature modifications which would bias the results. 
 
5.12. Lentivirus production 
In order to produce lentiviruses expressing E4, 293T cells were 
prepared for transfection in antibiotics-free medium and transfection took place 
with cells growing at 80% confluency using the calcium-phosphate method.  For 
1x 10cm∅ dish, 8µg of pRDI-282+E4, 4µg of pRDI275 and 4µg of pAD3 were 
used.  The medium was replaced 12-14 hours with DMEM supplemented with 
10% FCS and antibiotics.  The following day, the virus containing medium was 
collected, replaced and stored at 4°C.  Finally, 48 hours post-transfection, the 
medium was collected again and cells were discarded. 
To concentrate viruses, the collected media were first filtered through a 
0.22µm pore nitrocellulose filter.  Ultracentrifugation in a Centrikon T-1080 at 
50’000g for 130’ at room temperature without the brake was performed.  The 
supernatant was rapidly discarded and the pellet resuspended in 50µl PBS for 
each centrifugation tube.  The pellets were then pooled and rotated for 30-60’ at 
room temperature.  Aliquots were prepared and stored at -80°C.   
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5.13. Stable cell line establishment 
In order to have a homogeneous population of cells expressing E4 
upon addition of a chemical, the establishment of an inducible cell line was 
attempted.   
The S2.10 HeLa cell line was kindly provided by the Lingner lab.  This 
cell line already contains the Tet-responsive elements and lacks only the 
transgene under the control of a Tet-inducible promoter.  E4 was therefore 
cloned in the pTRE2-pur vector (Clonetech), using the BamHI and ClaI restriction 
sites, from the pMV11E4 vector. 
The cells were then selected with puromycin (2µg/ml) for 5 days, 
harvested and single-cell distribution in a 96-well plate was performed with a 
Becton Dickinson FACSorter.  After amplification of clones in medium containing 
puromycin, E4 presence was addressed by addition of doxycycline (1µg/ml) for 
24 hours followed by immunofluorescence.  
 
5.14. Atomic Force Microscopy 
In order to perform atomic force microscopy (AFM) experiments, an 
inverted fluorescence light microscope (Zeiss Axiovert 200) was equipped with 
an AFM apparatus (BioScope, VEECO Metrology Group).  The silicium nitrate 
tips were mounted on VEECO cantilevers and had an elongation constant of 0.06 
N/m.  The data were acquired with NanoScope (R) IIIa software (Digital 
Instruments) and processed through home made software built on MatLab Linux 
operation system. 
Several scans for each sample were performed with a scanning 
window of 10 x 10 µm and a 32 x 32 events definition.  Each cell was selected 
according to its fluorescence and to the absence of surrounding cells as 
observed with the optical microscope. 
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6. Results 
 
As the main goal of this project was to find a function in the viral life 
cycle for HPV16 E4, several directions were explored.  The Results chapter is 
separated into three parts.  In the first part, a method to introduce E4 as a protein 
into cells was tested, avoiding the problems related to the expression of the E4 
gene in mammalian cells.  These problems will be discussed later in this chapter 
as well as in the Discussion chapter.  In the second chapter, preliminary results 
for a potential novel function for E4 in the viral life cycle in relation to the 
differentiation of the stratified epithelium are presented.  The last chapter 
describes a direct analysis of the mechanical effects induced by E4 on live cells.  
This chapter uses a recent method applied to live keratinocytes known as the 
Atomic Force Microscope.  These experiments were done in collaboration with 
the group of Dr. Kasas at the Federal Institute of Technology in Lausanne (EPFL) 
and the method will be described in the same chapter.  
 
 
6.1. The production and purification of TAT-E4 fusion 
proteins and the transduction of fusion proteins into 
living cells. 
 
The expression of the E4 gene in mammalian cells seems to be 
somewhat stochastic.  The efficiency of transfection methods vary depending on 
the cell type and are difficult to reproduce.  In addition, the use of the Green 
Fluorescent Protein (GFP) as a reporter in the setting up of expression methods 
has proven not to be a reliable indicator.   
In order to introduce E4 into a cell in a more homogenous manner 
without using recombinant viruses or inducible cell lines, a protein transduction 
method was used.  It has been shown that fusing a TAT peptide sequence from 
HIV-1 to a target protein allows the fusion protein to enter the cell by freely 
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diffusing through the plasma membrane of living cells (Fawell et al., 1994; Vives 
et al., 1997).  In that perspective, a TAT-E4 fusion protein was designed and 
produced in E. coli bacteria.  The fusion protein comprises the TAT peptide 
followed by a Histidine stretch and a protease cleavage site.  Figure 12 shows a 
diagram of the construct.  The TAT domain, the Histidine stretch and the 
protease cleavage site are shown.   
 
 
 
 
 
 
 
 
By purifying the construct by using the Histidine stretch and NTA 
beads coated with Ni++, it was possible to obtain full length TAT-E4 as shown in 
figures 13 and 14.  As negative control, the empty vector expressing the N-
terminal part alone (TAT + His stretch) was used.  The purification procedure 
involves the collecting of fractions of eluted proteins, they are referred to fraction 
1 and 2 in the figure legends. 
Fig. 12:  Diagram of the TAT-E4 fusion protein.  The TAT domain (yellow), the 
Histidine stretch (red) and the protease cleavage site (green) are shown.  
E4TAT His 
∨ 
∧ 
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 1    2       3     4    5      6       7      8     9    10    11   12    13 
             Clone A                           Clone B 
175 kDa 
  83 kDa 
  62 kDa 
  47.5 kDa 
  32.5 kDa 
  25 kDa 
  16.5 kDa 
    6.5 kDa 
TAT-E4 
Fig. 13: Coomassie blue stained SDS-polyacrilamide 15% gel.  Total bacterial 
protein extracts were affinity-purified on a Ni++ column and separated on a 15% 
SDS-polyacrilamide gel.  1) Size marker, 2) Input, 3) Flow through, 4) 1µl eluted 
fraction 1, 5) 10µl eluted fraction 1, 6) 1µl eluted fraction 2, 7) 10µl eluted 
fraction 2, 8) Input, 9) Flow through, 10) 1µl eluted fraction 1, 11) 10µl eluted 
fraction 1, 12) 1µl eluted fraction 2, 13) 10µl eluted fraction 2. 
      TAT-E4                               TAT 
 1       2     3    4      5     6       7        8     9   10    11   12 
Fig. 14: Western blot showing the presence of full-length TAT-E4 as 
detected with an α-E4 antibody.  1) Input, 2) Flow through, 3) 1µl of eluted 
fraction 1, 4) 10µl of eluted fraction 1, 5) 1µl of eluted fraction 2, 6) 10µl of 
eluted fraction 2, 7) Input, 8) Flow through, 9) 1µl of eluted fraction 1, 10) 
10µl of eluted fraction 1, 11) 1µl of eluted fraction 2, 12) 10µl of eluted 
fraction 2.  Lane 7) shows a slight carry-over signal from lane 6). 
175 kDa 
  83 kDa 
  62 kDa 
  47.5 kDa
  32.5 kDa
     25 kDa
  16.5 kDa
    6.5 kDa
TAT-E4 
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One can see that the full-length TAT-E4 fusion protein was being 
produced and purified at the expected size of ~20kDa.  Another band is also 
seen at the size of ~40kDa, that could be a dimeric TAT-E4.  The nature of the 
analysis tells us that if this band is a dimeric form of TAT-E4, the proteins may be 
bound in a covalent manner.  In addition, a band with the size of ~10kDa is seen 
in the eluted fractions.  This band could correspond to E4 alone.  Either the 
bacteria did not make the first part of the fusion protein or bacterial proteases 
cleaved off the N-terminus.  In the input sample of the control condition, one can 
see a band at the same size as the full length TAT-E4 product.  This band is 
thought to be a “carried-over” signal from the neighboring sample and thus is not 
taken into account.  
By increasing the stringency of the purification step, it was possible to 
obtain almost pure TAT-E4 fusion proteins as shown in figures 15 and 16. 
 
 
 
            
            
            
            
Fig. 15: Coomassie blue stained SDS-PAGE gel showing purification efficiency.  
Two independent experiments were performed.  Lanes 1) and 6) Size marker, 
lanes 2) and 7) Input, lanes 3) and 8) Flowthrough, lanes 4 and 9) Eluted fraction 
1, lanes 5) and 10) Eluted fraction 2. 
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Purified TAT-E4 was then dialysed into DMEM (Gibco) and HeLa cells 
were incubated with 1µM of pure TAT-E4.  The immunofluorescence analysis 
shown in figure 17 was performed to check for cellular uptake and potential sub-
cellular localization. 
The immunofluorescence results show that TAT-E4 forms aggregates 
on the plasma membrane of the cells.  Confocal microscopy analysis confirmed 
the fusion protein accumulated on the outside of the cell (data not shown).  
Taken together, these results suggest TAT-E4 does not enter the cell.  It seems 
to form precipitates on the plasma membrane.  To try and diminish the 
precipitation of TAT-E4, the eluted fractions were dialyzed into various buffers.  
Fig. 16: Western blot of a gel ran in parallel to that in figure 15.  One can see full-
length TAT-E4 protein and a decrease in the amount of putative dimeric TAT-E4.  
Lanes 1) and 6) Size marker, lanes 2) and 7) Input, lanes 3) and 8) Flowthrough, 
lanes 4 and 9) Eluted fraction 1, lanes 5) and 10) Eluted fraction 2. 
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After dialysis, the solution containing the fusion proteins appeared to be cloudy, 
suggesting the solubility of the fusion protein was not improved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Though transduction with a TAT-GFP fusion protein was tested 
successfully during the setting up of the method, it appears the production and 
transduction of TAT-E4 faces problems.  This discrepancy suggests the solubility 
problem is due to the presence of E4 and not the TAT sequence.  Hence, 
subsequent work in this study was all done using gene-based protein delivery 
methods (plasmid transfection or plasmid electroporation). 
 
  30’  60’
180’120’ 
Fig. 17: Immunofluorescence images showing TAT-E4 localization.  Increasing 
incubation times (indicated) of TAT-E4 and cells did not change the distribution pattern of 
TAT-E4.  Localization to the membrane is seen but no cytokeratin pattern or clear 
intracellular distribution. 
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6.2. HPV16 E4 and the onset of epithelial differentiation 
 
At the beginning of the project, it was already known that E4 could 
localize to the cytokeratin network and collapse it into a cluster near the nucleus.  
Preliminary results also suggested E4 could subsequently localize to 
mitochondria and affect their distribution similarly.  These observations 
suggested E4 might undergo modifications in order to switch from a specific 
localization to another.  Thus, E4 was probed by western blotting over 3 days to 
see if any difference was noticed.  Surprisingly, the amount of soluble E4, initially 
high at day 1 post-transfection, dramatically decreased at day 2 and completely 
disappeared at day 3 as shown in figure 18.  This was tested in several cell lines, 
namely HeLa, U2OS and Saos-2.   
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Fig. 18:  HeLa (panel A), U2OS (panel 
B) or Saos-2 (panel C) cells were 
transfected with an E4-expressing 
plasmid or the control vector and cells 
were harvested at the indicated time 
points.  Presence of E4 was tested by 
western blotting.  A sharp decrease in 
the E4 amount is seen.  Panel A also 
shows the unphosphorylated form of 
E4. 
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To explain this striking decrease in E4 amount, it was hypothesized 
that the cells containing E4 were lost during the process of analysis.  Therefore, 
cells found in the culture medium (hence having lost their adhesion properties) 
were harvested and probed for E4.  The result is shown in figure 19. 
 
 
 
 
 
 
 
 
 
 
The initial conclusion from this experiment was that E4 accumulates 
over time in the cells having left their culture support.  The second observation 
was that there seems to be almost disappearance of E4 at day 2.  As these 
protein extracts are soluble proteins, it was then proposed to test insoluble 
proteins to see if E4 was found. 
 
 
 
 
 
 
 
 
 
 
 
 
    1           2          3            1            2           3 
Days post-
transfection 
          Adherent                         Non-Adherent
Fig. 19: Adherent and non-adherent HeLa cells transfected with an E4-
expressing plasmid were collected at the indicated time points and probed for 
E4 presence.  Accumulation of E4 in the non-adherent cells is seen. 
     1             2              3             1            2               3             1             1 
Adherent Non-Adherent Mock 
Adh 
Days post-
transfection 
Fig. 20: Analysis of insoluble proteins from HeLa cells transfected either with an E4-
expressing plasmid or with the mock vector.  Cells were collected from the indicated pool 
and at the indicated time points.  E4 is seen at all time points and in both pools of cells. 
Mock 
Non-Adh 
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Figure 20 shows that E4 is found in high amounts in the insoluble pool 
of proteins.  Insoluble proteins often tend not to be as rapidly degraded as 
soluble proteins.  Therefore, the amount of insoluble E4 is considered not to be 
representative of the expression of the E4 gene.  The soluble fraction seen in 
figures 18 and 19 might be a pool of E4 having a different function than the 
insoluble fraction. 
As the level of messenger RNA for a specific protein generally reflects 
the amount of protein produced, it was expected that the level of RNA encoding 
E4 would decrease.  To test this hypothesis, real-time PCR experiments were 
performed.   Because E4 is transfected into the cells, it was necessary to use a 
transfected non-regulated gene to serve as reference.  The zeocin resistance 
gene was therefore cloned into the same expression vector as E4 and co-
transfected in HeLa cells.  The results are shown in figure 21. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21: Real-time PCR experiments were performed to address the regulation level 
of E4 transcripts over time.  Comparison in between adherent and non-adherent cells 
is shown.  
Ct value differences between E4 and zeocin 
transcripts 
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The differences shown here are small (less than 2 Ct units) and not 
considered significant, suggesting the variation of the level of E4 messenger 
RNA does not reflect that of the level of the soluble E4 protein.  As the amount of 
cellular proteins are mainly regulated by the level of messenger RNA or by the 
stabilization of the proteins, it was hypothesized the increase in the amount of E4 
was achieved by an increase in its stability. 
This observed accumulation of E4 in the non-adherent pool of cells 
seen in figure 19 suggested that either E4 would be involved in the detachment 
of cells or that E4 is stabilized in cells in suspension.  The processes involved in 
the modification of the adhesive properties of cells include cell death and cellular 
differentiation.  These two processes were tested to see if E4 was involved in 
either one of them. 
The apoptosis of cells expressing E4 was tested by measuring the 
activation of Caspase-3, an effector caspase, and the release of Cytochrome C 
from mitochondria.  These results are shown in figures 22 and 23, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
The activation of caspases takes places through the cleavage of the 
full length inactive form to a shorter, active caspase.  Figure 22 shows the 
inactive form of caspase 3.  The membrane used for figure 22 was also exposed 
for different amounts of time to try and detect an active form of caspase 3.  It 
Fig. 22: Caspase-3 activation test.  HeLa cells were transfected with the indicated 
vector and collected at the indicated time points.  Full length (inactive) Caspase-3 is 
shown.   
 1          2         3        1        2        3         1       2     
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Days post-
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appeared no shorter form was made as longer exposures of the film only resulted 
in dark rectangles of the size of the whole membrane.  In addition, the absence 
of full length caspase 3 in non adherent cells at days 1 and 2 is yet unclear. 
 
To test the release of cytochrome C from mitochondria, cytoplasms of cells 
transfected with a plasmid expressing E4 or the empty vector were incubated 
with extracted mitochondria.  The presence of cytochrome C in the supernatant 
was then measured by western blotting. 
 
 
 
 
 
 
 
 
 
 
 
In the experiments shown in figures 22 and 23, there was no evidence 
that the presence of E4 significantly increased the activation of caspase 3 or the 
release of cytochrome C from mitochondria.  Hence, no evidence supported the 
hypothesis that E4 triggered apoptosis in HeLa cells.  Therefore, the detachment 
of cells from the culture surface in the presence of E4 did not appear to involve 
the induction of programmed cell death. 
Alternatively, and as mentioned above, another process cells undergo 
that affects the adhesive properties of cells is differentiation.  To test rather E4 
can trigger differentiation and therefore modify the adhesion of keratinocytes, E4 
was introduced into keratinocytes.  As the process of differentiation is 
accompanied by the increase in differentiation markers found in the cells, as 
illustrated in figure 6, the presence of such markers was tested.   
pMV11E4Mock 
  25µl            5µl            25µl           5µl            25µl 
12 hrs post-
transfection 
24 hrs post-
transfection 
Cytochrome C 
Fig. 23: Cytochrome c release test.  The presence of cytochrome C was probed in the 
indicated amounts of supernatants having undergone the indicated treatments. 
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It was chosen to test the presence of involucrin as it is an early 
differentiation marker. 
 
 
 
 
 
 
 
 
 
 
 
 
The accumulation of involucrin in E4-containing cells seen in figure 24 
suggests the differentiation process has begun, hence modifying the adhesive 
properties of the cell and promoting its detachment.  It has been reported that the 
involucrin gene promoter is calcium dependent (Eckert et al., 2004).  As calcium 
is often used as a positive control for epithelial differentiation, the possibility that 
the involucrin expression would be the direct consequence of the presence of 
calcium and not the consequence of the initiation of differentiation rendered the 
use of calcium in the culture medium as positive control impossible.  A positive 
control could have been the use of organotypic raft culture cells or skin biopsies.  
In addition, the use of HeLa cells regarding the onset of differentiation is not ideal 
as they are transformed cells, hence not easily prone to differentiate.  They were 
used here because of their high transfection efficiency in our hands. 
As involucrin is an early marker for differentiation, the presence of later 
markers of differentiation was tested.  The presence of filaggrin and loricrin as 
late markers of differentiation was not detected (data not shown).  This result 
suggested that, at least in these cells, E4 was able to initiate only the early steps 
of differentiation of HeLa cells. 
Fig. 24:  Involucrin in E4-expressing cells.  HeLa cells were transfected with the 
indicated plasmids.  The non-adherent cells were then harvested at the indicated 
time points and western blot analysis was carried out.  The accumulation of 
involucrin is seen in the presence of E4. 
Days post - 
transfection 
1          2            3            1           2 3
pMV11E4 pMV11
Involucrin 
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As differentiation is accompanied by an intracellular increase of free 
calcium from the intracellular calcium stores such as mitochondria or the 
endoplasmic reticulum, which would also explain the involucrin increase, FACS 
analysis to measure the amount of free cytoplasmic calcium was performed.  By 
incubating cells with a specific dye (Indo-1), they exhibit a fluorescent signal 
which is dose-dependent on the amount of free cytoplasmic calcium; the result is 
shown in figure 25. 
Saos-2 cells, which do not contain cytokeratins, were chosen to test 
this hypothesis to avoid the cytokeratin localization of E4 and favor a direct 
targeting of the mitochondria to see if a release of calcium into the cytoplasm 
would occur.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Untreated cells, day 1 Mock transfected cells, day 1 E4 transfected cells, day 1
Mock transfected cells, day 2 E4 transfected cells, day 2
Fig. 25: Saos-2 cells were transiently transfected with an E4-expressing plasmid or the 
mock control vector and stained 30 min with Indo-1.  Cells were collected at the 
indicated time points and subjected to FACS analysis.  The unprocessed data are 
shown. 
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This method is often used in immunology where the activation of T-
cells results in an increase of free cytoplasmic calcium.  The expected pattern for 
an increase in free calcium would be an upward shift of the fluorescent signal. 
As shown in figure 25, from the E4-expressing cell population, no 
significant increase of free cytoplasmic calcium is observed in the presence of E4 
although some cells with higher fluorescence were seen.  As the potential 
increase in free calcium seemed to only be a minor contribution to the 
accumulation of involucrin, the level of messenger RNA encoding involucrin was 
measured by real-time PCR to further test the hypothesis that the accumulation 
of involucrin could be due to stabilization of the messenger RNA.  Indeed, if the 
transcription is not further increased, a stabilization of the messenger RNA would 
result in the increase in the level of messenger RNA encoding involucrin.  The 
GAPDH house-keeping gene was used as reference. 
 
 
Fig. 26: Real-time PCR experiments showing the effect of E4 on the level of the 
involucrin messenger RNA. 
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The difference in between the GAPDH transcripts and the involucrin 
transcripts reflects the specific modifications the level of the involucrin 
messenger RNA.  As a low amount of messenger RNA results in a high Ct value, 
the pattern seen in figure 25 for the non-adherent cells suggested there was 
slightly more RNA in non-adherent cells expressing E4 at day 3 than non-
adherent cells not expressing E4 at day 3.  Once again, the margin of error for 
this type of experiment is of 2 Cts.  It appears therefore the difference of RNA 
level is within this margin, hence the result is uncertain. 
As for the E4 protein, it appeared the accumulation of involucrin in the 
non-adherent cells is at most only partially due to an increase in the level of 
messenger RNA.  A stabilization of the involucrin protein would better explain the 
accumulation observed by western blotting in non-adherent cells expressing E4.   
Some reports support this hypothesis.  Indeed, in differentiating 
keratinocytes, the transglutaminase enzyme is activated.  Its role includes the 
cross-linking of proteins such as involucrin (Candi et al., 2001)  This cross-linking 
activity increases the cells mechanical integrity and helps it to face hazards from 
the environment.  Therefore, if E4 can initiate the first steps of differentiation, the 
activation of transglutaminase would cross-link involucrin, rendering it more 
stable.  Hence, the accumulation of involucrin seen in the presence of E4 would 
rather be a stabilization of the protein rather than the activation of transcription or 
the stabilization of the messenger RNA allowing increased translation and 
therefore accumulation of involucrin. 
As E4 is a cytoplasmic protein, a direct effect of E4 as a transcription 
factor is not expected.  It could nevertheless act through retaining transcription 
factors out of the nucleus.  But the results obtained suggest E4 acts rather on the 
stability of involucrin, possibly through increasing the activity of transglutaminase 
enzymes.  It would be of interest to test this hypothesis in non-adherent cells 
expressing E4. 
Altogether, these results suggest E4 might be able to help 
keratinocytes to undergo the initial steps of differentiation.  No mechanism has 
been proposed yet.   
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6.3. The mechanical properties of cells expressing E4 
explored with the Atomic Force Microscope 
 
As mentioned above, E4 is able to collapse the cytokeratin network 
into a cluster near the nucleus within 20 hours.  As E4’s presence in low-grade 
lesions occurs at high levels in the upper layers of the stratified epithelium, it has 
been proposed that E4 has a function in the release of newly made viral 
particles, through affecting the mechanical properties of cells by collapsing the 
cytokeratin network.  To address this possibility, the use of Atomic Force 
Microscopy (AFM) was chosen in collaboration with the group of Dr. Kasas at the 
Federal Institute of Technology in Lausanne (EPFL).   
This microscope is not an optical microscope.  Its probe comes into 
very close proximity to the sample and tests the local mechanical properties 
found.  In this view, the AFM is mounted on an optical microscope equipped with 
fluorescent light.  This additional feature allows the user to locate cells showing 
green fluorescence or not. 
Apart from having to mimic conditions found in an incubator to be able 
to analyze living cells, the nature of the microscope and of E4 brings two major 
problems to light: first, one has to be sure the cell being analyzed expresses E4.  
Second, the growing cells must not be at high confluency, which is in conflict with 
most transfection methods used. 
To try to solve these problems, I initially designed an E4-inducible cell 
line (Tet-on).  An inducible cell line would allow us to have a homogenous 
population expressing E4 upon addition of tetracycline, avoiding the problem of 
knowing whether the analyzed cell expresses E4 or not.  This method would also 
allow us to circumvent the technical issue of having cells grow at a low density.  
Two successive attempts were not successful.  When amplifying a clonal 
population, it appeared only about 30% of the cells expressed E4 as assayed by 
immunofluorescence.  When sub-cloning cells from an amplified cell clone, again 
the E4 expression was heterogenous and showed only 30% of the transgene 
expression.  The design of an inducible cell line was therefore set aside. 
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Second, a plasmid was designed in which the E4 cDNA was followed 
by a translation stop (not a transcription stop), an internal ribosome entry site 
(IRES) and finally EGFP cDNA.  In theory, this strategy should ensure that if GFP 
is expressed, then the cDNA located in front of the IRES should also be 
expressed because the messenger RNA is the same for both open reading 
frames.  This method gave unexpected results in which cells expressing GFP 
expressed E4 in only about 25-30% of cases as illustrated in figure 27. In 
addition, a few cells expressing E4 didn’t express GFP.  Therefore, this method 
was not usable.   
                    
                     
 
 
 
Third, an electroporation method to introduce DNA into HeLa cells was 
set up.  The GFP reporter used was expressed in about 40% of cells, 
independent of the cell density at which the culture was carried out.  When E4 
was tested with the best conditions, no cell expressed E4 at all.  Varying the 
culture density did not affect E4’s expression. 
Fourth, co-transfection of an E4- and a GFP-expressing plasmids in a 
ratio of 3:1 was tested as described in the Materials and Methods section.  The 
density problem was avoided by performing part of the transfection in suspension 
Fig. 27: Representative example of an immunofluorescence analysis of HeLa 
cells transfected with a plasmid encoding E4-IRES-GFP.  E4 is in red, DNA is 
blue and GFP is green.   
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in a bacterial culture dish, preventing the cells from adhering to the surface.  After 
90’, the cells were collected and seeded on mammalian culture dishes to the 
desired density, previously coated with a solution containing fibronectin and 
collagen mimicking the extra-cellular matrix.  Using this method, cells expressing 
high amounts of GFP express E4 in sufficient amounts in about 70-80% of cases 
as shown in figure 28. 
Therefore, for experiments carried out with the AFM, HeLa cells were 
co-transfected the previous day and seeded at the appropriate density 18-20 
hours prior to analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 28: Representative immunofluorescence of cells co-transfected with an E4- and a 
GFP-expressing plasmid.  E4 is detected by indirect immunofluorescence in the Cy3 
channel (red) while GFP is green and DNA is blue.   
Merge
E4GFP 
 DNA 
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The initial experiments were done to test if HeLa cells would not be 
perturbed by the use of the AFM.  The same experiments also allowed to test 
whether HeLa cells were suitable for analysis by the AFM.  Indeed, cells must not 
be too “high” in order to have a reference (such as the culture dish surface) and 
be able to scan over the cell without breaking the cantilever during a single data 
acquisition.  It appears the HeLa cell body is too high whereas cellular 
projections (or pseudopods) are usable. 
Therefore, in order to make sure pseudopods were suitable for this 
type of analysis, immunofluorescence experiments were performed to test the 
presence of cytokeratins in cellular projections.  Figure 29 shows the presence of 
cytokeratins throughout the cell, including the cellular pseudo-podes, hence 
validating the use of cellular projections to test the effect of E4 on the mechanical 
properties of the cell through the collapse of the cytokeratin network. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 29: Immunfluorescence experiments performed on untreated HeLa 
cells. Cytokeratins are shown in green, DNA in blue. 
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The scanning window for the AFM must be pre-defined, in our case 
10µm x 10µm, and the definition must also be determined, here 32 x 32 events 
(also called pixels).  The software then builds an image showing the topology of 
the sample and paints the mechanical properties using a color-code (an example 
is shown in figure 11: a HeLa cellular projection and its mechanical properties).   
The force curves obtained for each pixel are translated into two 
pictures as shown in figure 30: the first gives the topology of the sample and 
corresponds to the height of the sample detected at the beginning of the 
deflection of the cantilever.  The second corresponds to the distance the cell can 
be locally depressed when the cantilever reaches the fixed maximum deflection.  
If the depression distance is small, the sample is hard, if the depression distance 
is larger, the sample is softer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The software can then blend the data to obtain a smoothened 3-D 
image as shown in figure 31. 
 
A B
Fig. 30: Unprocessed images obtained from the force curves data acquired on 
a HeLa cell.  Panel A) beginning of indentation, panel B) end of indentation.  
The brighter the color, the higher the sample. 
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Experiments with cells expressing GFP and E4 were performed in 
parallel with cells expressing GFP alone.  The data obtained were not processed 
to 3D images but only images as seen from the top of the cell.  Figures 32 and 
33 show examples of results obtained.   
 
 
 
 
 
 
Fig. 31:  3-dimension image obtained by blending the data from “beginning of deflection” 
and “end of deflection” images.  The topology is the true topology of the cell and the color 
code reveals the local mechanical properties of the cell.
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A B
C D
Fig. 32:  AFM images of GFP-negative (panels A and B) and GFP-positive (panels 
C and D) HeLa cells.  GFP positive cells are considered to express E4.  
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Isolated cells expressing high levels of GFP were chosen using the 
fluorescent light whether the cells had been transfected with a GFP-expressing 
vector alone or co-transfected with a GFP- and an E4-expressing plasmid as 
described in Materials and Methods.  The scanning window was then assigned to 
a pseudopod and number of events was set.  The scanning of a 10µm x 10µm 
window took about 300 seconds. 
Because of the sensitivity of the method, there are a number of factors 
that influenced the quality of the acquisition, such as people walking in the same 
room as where the AFM is found, or talking loudly.  Therefore, many samples 
had to be scanned in order to obtain valid data. 
Valid data were then processed by home made software into images 
such as shown in figures 31 to 33.  From the analysis of the images, it appeared 
the mechanical properties of the cells expressing E4 were less homogenous.  
E F 
A B C D 
G H 
Fig. 33: AFM images of HeLa cells transfected either with a GFP-expressing plasmid alone 
(panels A – D) or co-transfected with a GFP-expressing plasmid and an E4-expressing 
plasmid (panels E – H).  The black and white images (panels B, D, F and H) show the 
height of the sample and the panels A, C, E and G show the local mechanical properties.  
Using the black and white images, one can localize where the cell is within the frame (all 
pictures are at the same magnification).  Color-code: black and white images: white is high, 
black is low; color images: red is hard, blue is soft. 
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Indeed, GFP-negative cells or cells expressing only GFP show a rather “smooth” 
surface whereas cells expressing E4 show a more “bumpy” profile.   
As each pixel of the image is associated to a numerical value, it was 
hypothesized that if the cells expressing E4 showed a more “bumpy” profile, the 
distribution of the numerical values should be broader than when E4 is not 
expressed.  Therefore, the standard deviation for each sample was calculated 
and the result is shown in figure 34 and 35. 
 
      
 
 
 
Fig. 34: Standard deviation of the distribution of the numerical values associated to the 
mechanical properties of 8 cells transfected either with a GFP-expressing plasmid alone (blue) 
or co-transfected with a GFP-expressing plasmid and an E4-expressing plasmid (red). 
Fig. 35: Average of the standard deviations shown in figure 34.  Error bars are shown. 
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The results shown in figures 34 and 35 suggested the presence of E4 
in cells, and hence the collapse of the cytokeratin network, affected the 
mechanical properties of the cells.   
This could be explained by the possibility that E4 having collapsed the 
cytokeratin network, the hemidesomosmes do not have anymore support 
beneath.  Therefore, when scanning these precise areas, the microscope senses 
that the anchoring of the cytokeratins has disappeared, hence showing areas 
“softer” than if the hemidesmosome was still supported by the normally 
underlying cytokeratin network. 
It is generally thought the levels of the microtubule and actin 
components of the cytoskeleton are low in terminally differentiating keratinocytes 
(Presland et al., 2001).  However, the cells used in the present experiments 
contain microtubules and actin cytoskeletons, therefore showing a “bumpier” 
profile when only the cytokeratin network is collapsed.  As the late stages of the 
viral life cycle, where E4 is expressed in high amounts, take place in the upper 
layers of the stratified epithelium, to try and mimic further this situation, chemical 
reagents will be used to depolymerize the latter networks.  Nocodazole and 
Cytochalasin D will serve to affect the organization of microtubules and actin 
respectively.  To eliminate any effect of E4 on the activity of the chemicals to be 
used, immunofluorescence experiments will be performed as controls before 
addressing the mechanical properties of cells having lost their microtubule, actin 
and cytokeratin networks using the AFM. 
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7. Discussion 
 
Among malignant lesions, cancer of the cervix is highly represented 
and the fifth cause of cancer associated female death worldwide.  It is thought to 
be the consequence of infection by human papillomaviruses (HPV).  When 
biopsies are analyzed for presence of viral DNA, about 50% of cases show HPV 
type 16 (HPV16) DNA.  The study of this virus has therefore been the focus of 
many laboratories and is the aim of this thesis. 
The HPV16 life cycle is poorly understood, the most evident trait is that 
it is tightly linked to the differentiation process of the infected keratinocyte.  It has 
been possible to show the presence of various viral proteins in low-grade lesions 
at different stages of the differentiation process.   
Interestingly, the E4 gene product has been shown to be abundantly 
present in the late stages of the viral life cycle.  Many studies have been carried 
out to assign a viral function to E4 but they have not been so far successful.  
Here, several approaches were used to address this point. 
 
7.1. The TAT-E4 fusion protein 
 
To introduce E4 into mammalian cells using conventional methods 
such as transfection has proven to be unreliable.  Therefore, to circumvent this 
problem, a fusion protein with the short basic TAT sequence, originating from the 
TAT protein of the human immunodeficiency virus type 1, and E4 was designed, 
produced in bacteria and purified.  Preliminary tests showed that the fusion 
protein precipitated on the surface of the cells.  To avoid this, dialyzing the 
protein into either DMEM or PBS was tested and incubation on the live cells, 
once again, showed precipitation on the surface on the cells.  This method was 
then given up and an approach focusing on optimizing the more common 
methods pursued. 
A major problem in designing fusion proteins with E4 is the small size 
of E4.  Though the TAT sequence itself is rather short, the purification protocol 
 74
proposed uses a His stretch.  To these two sequences, spacers and a proteolytic 
cleavage site must be added to avoid the fusion protein diffusing out of the cell in 
the same way it went in.  For the TAT sequence to be exposed and to permit 
diffusion across the plasma membrane, TAT fusion proteins are usually 
denatured in urea.  This denaturation, apart from exposing the TAT sequence, 
most often affects the activity of the construct.  The chaperone family of cellular 
proteins is thought to be able to refold transduced fusion proteins, in some cases 
after the tag has been cleaved off by cellular proteases, resulting in a pool of 
correctly refolded and active exogenous proteins. 
The size of the target protein affects the propensity of the denatured 
peptide to refold correctly and recover its initial activity.  In the case of E4, its 
small size suggested it would be a good candidate for a TAT fusion protein, 
being able to recover its normal three dimensional configuration with relatively 
high occurrence.  Unfortunately, it was not predictable that the construct would 
precipitate.  Though several conditions were tested, including various salt 
concentrations and glycerol amounts, no condition was suitable to provide 
soluble TAT-E4 fusion proteins able to penetrate cells. 
Interestingly, the solubility problem seemed to be specific to E4 as 
other TAT fusion proteins were produced in the lab and exhibited intra-cellular 
localizations and functions.  Also, a TAT-GFP construct was produced and 
purified.  Even in high concentrations of urea, the green color could be seen, 
suggesting the three dimensional configuration was not completely lost.  Tests on 
live cells showed TAT-GFP could penetrate cells and be maintained without 
significant exiting of the cell. 
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7.2. The involvement of E4 in initiating the onset of 
epithelial differentiation 
 
When the project started, it had been shown that E4 co-localized with 
the cytokeratin network and reorganized it.  There were also strong indications 
that E4 could then leave the cytokeratins, target mitochondria and reorganize 
them as well.  The possibility that E4 changed with time was proposed.  The 
initial results obtained by western blot analysis suggested that E4 disappeared 
rapidly, and within 72 hours, was no more detectable in the soluble pool of 
proteins (Fig. 17).   
The hypothesis that the cells containing E4 were lost in the process of 
analysis was then proposed.  To test it, the cells found in the medium, therefore 
having lost their adhesive properties, were collected by centrifugation and tested 
for the presence of E4 by western blot (Fig. 18).  Surprisingly, an accumulation of 
E4 was observed in the non-adherent cells.   
The question of knowing if E4 triggered the detachment of the cells 
from the plate or if cells in suspension allowed the accumulation of E4 had to be 
addressed.  To do so, HeLa cells were grown in bacterial culture dishes, in which 
cells are unable to adhere to the surface.  The presence of E4 was tested by 
western blotting as before but no accumulation of soluble E4 was detected (data 
not shown).  This led to the hypothesis that E4 is the cause of the detachment of 
cells.   
There are mainly two processes by which cells lose their adhesive 
properties: the first would be through apoptosis and the second through 
differentiation.  The possibility that E4 would trigger necrosis of cells was set 
aside as the morphology of the cells in suspension did not correspond to necrotic 
cells.  To address the possibility that E4 might induce apoptosis, the release of 
cytochrome C and the activation of caspase 3 were tested (Figs. 21 and 22).  To 
test the release of cytochrome C, mitochondria were purified from untreated cells 
and incubated with various amounts of cytoplasms of cells transfected with an 
E4-expressing plasmid.  As cytochrome C was not released at a higher level with 
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E4 than without, and as no significant caspase 3 activation was detected, by 
these assays, the hypothesis that E4 could trigger the lift off of cells through 
activation of apoptosis was set aside.  Nevertheless, it has been reported that 
cells expressing E4 could show signs of apoptosis as measured by annexin V 
staining (Raj et al., 2004).  The possibility that E4 induces apoptosis in 
keratinocytes may not be sufficient to explain why soluble E4 is found exclusively 
in non-adherent cells 72 hours post-transfection.  Indeed, the authors see 
apoptosis occurring in 30% of the cells expressing E4, whereas 70% of the cells 
do not show annexin V staining.  Apoptosis is considered to contribute to the 
detachment of cells expressing E4, in parallel to another mechanism. 
To test the last hypothesis, the appearance of a keratinocyte 
differentiation marker was tested.  One, two and three days post-transfection, the 
non-adherent and adherent cells were harvested and probed by western blotting.  
The accumulation of involucrin in cells expressing E4, and in particular in non-
adherent cells, suggested E4 could trigger the initiation of differentiation.  As the 
system used is based on HeLa cells, and because these cells are thought to be 
difficult to differentiate, it would have been interesting to test the appearance of a 
differentiation marker in primary keratinocytes.  However, the production of 
lentiviruses expressing E4 for use in this experiment was not successful, again 
probably reflecting the difficulty in expressing E4 and the effect of this protein on 
cells. 
A closer analysis at the mechanism causing the accumulation of 
involucrin has suggested it is probably not a transcriptional regulation, but rather 
due to the decrease of its degradation.  This model fits with the fact that in vivo, 
involucrin is cross-linked by transglutaminases rendering its degradation more 
difficult.   
As involucrin is an early marker of differentiation, later markers such as 
loricrin and filaggrin were also tested.  Unfortunately, it was difficult to find 
antibodies targeting human filaggrin or loricrin usable in our assay. Therefore, 
antibodies initially targeting the markers found in mice were used.  These 
antibodies have been shown to be cross-reactive with the human proteins 
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(Marjorie Guitard, personal communication).  However, no evidence supported 
the expression of either filaggrin or loricrin in HeLa cells expressing E4.  These 
results suggested E4 could induce only the onset of differentiation without 
supporting the later stages of differentiation in HeLa cells. 
In view of what is known about the life cycle of the virus, the 
hypothesis that E4 could help the cells to undergo differentiation makes sense.  
Indeed, the E6 and E7 oncogenes force the cell to provide an S-phase like milieu 
in order perhaps to allow the amplification of the viral genome.  But it is also 
known that the infected cell must go through the differentiation process to permit 
the expression of all viral genes and in particular the late genes L1 and L2 to 
assemble functional viral particles.   
In the context of the epithelium, the cells surrounding the infected cell 
provide signals to trigger the differentiation process but these signals are 
probably silenced by the E6 and E7 proteins sufficiently to maintain the pseudo-
S-phase milieu.  If E4 can provide the extra signal to induce the infected cell to 
initiate differentiation at a certain point in the lytic cycle, this would allow the rest 
of the viral life cycle to take place. 
Low grade lesions are warts, which exhibit a hyper-proliferation of the 
basal cells of the epithelium but maintain all the later stages and layers of 
stratified epithelium, suggesting the pathway of differentiation is only delayed in 
comparison to non-infected cells.  As the expression of E4 in the early stages of 
the viral life cycle is thought to be low, one could imagine an accumulation of E4 
is needed to reach the threshold before sufficient signals to start differentiation 
are provided.   
The pattern of expression that E4 shows in the upper layers of the 
epithelium and the reorganization of the cytokeratin network suggest that E4 may 
be involved to some degree in this model.  Indeed, it has also been shown that 
E4 can co-localize with plectin and collapse it in a similar manner as cytokeratins 
(Samuel Berguerand and Ken Raj, personal communication).   
Plectin is a 500kDa protein found in the hemidesmosomes which are 
structures located in the plasma membrane.  Plectin also cross-links elements of 
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the cytoskeleton together to stabilize the network.  One of the functions of 
hemidesmosomes is to hold the cytokeratin filaments attached to the cytoplasmic 
membrane.  Hemidesmosomes are also the area where integrins are found.  The 
α6 and β4 heterodimers of integrins are specifically found on the surface of basal 
keratinocytes and allow the cell to lie on the basal lamina.  If hemidesmosomes 
are destabilized by the loss of plectin, would the integrins also be destabilized 
and no more serve as adhesion molecules?  Would this loss of adhesion suffice 
to signal to the cell to begin its differentiation process?  To address this question, 
HeLa cells were grown on coating solution (containing fibronectin and collagen 
which are components of the basal lamina) and the presence of α6 and β 
integrins was tested by immunofluorescence (data not shown).  It appears these 
integrins have a high rate of turn-over, and the majority of the signals were seen 
within the cytoplasm, possibly due to proteins being either synthesized or 
transported to the membrane.  Some signals were seen at the plasma membrane 
but they did not represent the majority.   
Nevertheless, and to further address this hypothesis, HeLa cells were 
grown in bacterial culture dishes, not allowing the cells to adhere on the surface, 
therefore preventing the integrins signaling into the cell.  The presence of 
involucrin was then tested by western blotting.  No signal was detected (data not 
shown) suggesting that the detachment of cells from the culture surface is not 
enough to trigger the differentiation process. 
It would be of interest to address the hypothesis that E4 could help 
keratinocytes to differentiate in the context of organotypic raft cultures using the 
whole viral episome with wild type E4 or an episome not being able to produce 
E4 proteins (affecting either the splice sites or introducing a stop codon, but 
without affecting the overlapping E2 amino acid sequence).  Would the 
differentiation process take place as in low grade lesions or would it be delayed, 
or even prevented?  Would the late viral genes be expressed?  With CRPV, Peh 
et al. observed no L1 production in the absence of E4.  To answer these 
questions would be of great interest in view of the viral life cycle but also might 
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help understand the complicated mechanisms involved in epithelial 
differentiation. 
 
7.3. The Atomic Force Microscopy and the modification 
of the cellular mechanical properties by E4  
 
As mentioned above, it has been reported that E4 co-localizes with the 
cytokeratin network and collapses it into a cluster near the nucleus.  Because this 
observation in vivo takes place in the late stages of the viral life cycle, and hence 
in the upper layers of the differentiating epithelium, it has been proposed that 
rearranging the cytokeratin network might affect the cell’s mechanical properties 
in a way that might facilitate the release of newly made viral particles. 
A technique, originally used by physicists and modified by biologists, 
allows us to address this question.  Fortunately, we have had the possibility to 
collaborate with a group from the Federal Institute of Technology in Lausanne 
(Switzerland, EPFL) who use the atomic force microscope (AFM) as a tool to 
address directly the mechanical properties of live biological samples.  Their work 
focuses mainly on neurons or elements found within neurons.  Because they 
have been able to detect modifications of the cell’s mechanical properties by 
altering the actin network or the microtubule network in axons, we assumed it 
would be possible to detect changes in the mechanical properties of 
keratinocytes having modified their cytokeratin network. 
The main problem we had to face was to make sure the cell analyzed 
with the atomic force microscope expressed E4 and has collapsed its cytokeratin 
network.  Indeed, as discussed, the expression of E4 is somewhat stochastic and 
to identify cells that do express E4 is not trivial.  As the AFM is mounted on an 
optical microscope equipped with fluorescent light, the use of GFP as a reporter 
was possible.  The easiest would have been to tag E4 with GFP but 
unfortunately, the tag would have been about three times the size of the target 
protein.  In addition, since both the N-terminal and C-terminal domains of E4 are 
necessary for the protein to co-localize with and reorganize the cytokeratin 
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network, the tag might have interfered with the activity of E4.  Lastly, a C-terminal 
GFP tagging of E4 was found in our lab to inactivate the GFP moiety rendering 
the tag useless (Samuel Berguerand, personal communication). 
The second most efficient possibility would be to design an inducible 
cell-line expressing E4 from a tetracycline-inducible system.  To obtain such a 
cell-line has proven difficult as the clonal expansion of selected cells gave rise to 
heterogeneous expression of E4.  The goal of having a homogenous population 
of cells expressing E4, avoiding the use of a fluorescent reporter, was not 
reached. 
It was then concluded that the co-transfection of vectors expressing 
either E4 or GFP would be the best way to localize cells expressing E4.  The  
AFM calls for cells growing at low density as neighboring cells could interfere 
with the analysis.  This is in conflict with the usual and efficient methods of 
transfection which require cells growing at least at 70-80% of confluence.  In 
addition, cells are analyzed 20 hours post-transfection, giving enough time for 
cells to grow to a higher density. 
To try and circumvent this drawback, a co-electroporation protocol was 
set up as this method would allow seeding of cells to any desired density.  Most 
protocols for electroporating mammalian cells target cells growing in suspension.  
The technique had to be adapted to keratinocytes.  GFP served as reporter gene 
to perform all the tests, which reached a reasonable amount cells expressing the 
transgene.  But when co-electroporation of GFP and E4 was tested with the 
same protocol, it appeared that no cells expressed the viral protein at all while 
some cells expressed GFP. 
Finally, it was then proposed to modify a standard lipofection-based 
protocol to transfect adherent cells.  Before transfection, HeLa cells growing at 
the density allowing normal transfection (in our case 90-95%) were harvested by 
trypsinization and mixed with the expression vector(s) in a small volume.  The 
resulting suspension was then transferred to a bacterial culture dish, avoiding 
that the cells adhere on the surface, and incubated 90’ at 37°C with 5% CO2.  
Following the incubation step, the cells were collected and seeded to the desired 
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density in mammalian culture dishes.  This method seemed to give satisfactory 
results where the same fraction of cells expressed GFP as when transfected 
according to the manufacturer’s protocol. 
The introduction of the E4 gene was then performed in two different 
manners.  The first was the cloning of an internal ribosome entry site followed by 
the GFP cDNA after the E4 cDNA but before the transcription stop signal.  The 
idea was that the same messenger RNA encodes the E4 and GFP proteins 
suggesting that if GFP is made then E4 must be made as well.  
Immunofluorescence analysis has proven that while GFP is expressed in 
sufficient amount of cells, it does not correlate with the presence of E4.  The 
second was to co-transfect two vectors expressing either E4 or GFP to different 
ratios.  After a series of tests, a ratio of 3:1 E4 to GFP seemed to be the best 
proportion.  For all the experiments performed with AFM, HeLa cells were 
therefore co-transfected with plasmids expressing either E4 or GFP to a ratio of 
3:1 in bacterial culture dishes before being diluted to the desired density in 
mammalian culture dishes. 
Once all the setting up for the experiments was performed, the first 
analyses with AFM were aimed at making sure that the keratinocytes could be 
used.  Indeed, the cantilevers have a limited amplitude of indentation before 
breaking.  In addition, in the course of a single data acquisition, one must have a 
reference to tell the software what is considered as being a hard surface, i.e. the 
culture dish surface in our case.  It appears the body of HeLa cells, especially 
where the nucleus is found, is usually too high to be scanned together with the 
culture surface.  We therefore could scan only the cellular projections 
(pseudopodes). 
The results obtained with cells expressing E4 suggest the mechanical 
properties of cells with reorganized cytokeratin networks are locally modified.  It 
should also be kept in mind the cells shown in figure 33 for the samples co-
transfected with a GFP-expressing plasmid and an E4-expressing plasmid 
(considered as being E4 positive) may not express E4.  As among the co-
transfected cells shown in figure 33, at least one shows a standard deviation 
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close to the cells transfected with the GFP-expressing plasmid, if that particular 
cell does not express E4, then the result for the co-transfected cells shown in 
figure 34 would differ yet more than the result for cells transfected with the GFP-
expressing plasmid alone.  If so, this provides extra support for the model that E4 
does affect the mechanical properties of keratinocytes.   
When this result is transposed to terminally differentiating 
keratinocytes, containing a high amount of cytokeratins and less microtubules 
and actin, one can propose the collapse of cytokeratins will affect substantially 
the mechanical properties of such cells.  In the context of the viral life cycle, a 
potential function for E4 could then be to affect the cell’s physical integrity to 
facilitate the release of newly made viral particles to the environment.   
This hypothesis would also explain why such amounts of E4 are made.  
Indeed, the abundance of E4 suggests a structural role for E4.  This is not 
exclusive and E4 could exert several functions at the same time, some of them 
requiring smaller amounts.  But it seems reasonable to propose at least a 
structural function in the HPV16 viral life cycle for E4. 
To test this model, the release of virus-like particles (VLPs) in the 
presence or in the absence of E4 could be quantified.  By producing capsid 
proteins in mammalian keratinocytes that express E4 or not, and then by 
quantifying the amount of VLPs found in the culture medium, one could evaluate 
the contribution of E4 to the release of viral particles from the cytoplasm into the 
environment.  To quantify pseudo-virions, a possible method would be the use of 
an enzyme-linked immunosorbant assay (ELISA) on culture medium samples.  
Alternatively, an immunoprecipitation against capsid proteins on defined volumes 
of the culture medium could be performed.  To follow it by a low concentration 
PAGE and silver staining of the gel would provide quantification of the amount of 
viral particles present.  If these assays show the presence of viral capsid 
proteins, electron microscopy on deposited and desiccated samples of culture 
medium of a known volume could be performed.  It would allow to verify whether 
the capsids are correctly assembled and to evaluate the amount of viral particles 
released. 
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The production of HPV16 pseudo-virions in mammalian cells has 
proven not to be easy, therefore the choice of the viral capsids to be made will be 
a crucial decision.  For example, the capsid must not be made to a too high level 
to avoid the lysis of the cell in the absence of E4.  It must also be able to be 
assembled in a keratinocyte and have, if possible, the same intracellular 
interactions as the wild type HPV16 viral particle.  All these constraints render the 
testing of this model challenging. 
 
 
8. Conclusion 
It appears that the nature of the replicative niche of HPV16 itself 
constitutes a significant draw-back in the study of virus’ life cycle. 
Moreover, among the HPV16 encoded proteins, the E4 protein is 
particular challenging, due to its biochemical properties and effects on cells.   
Because it is expressed at such high levels in low-grade lesions, it is likely to 
have a significant role.  Nevertheless, no direct evidence for a specific function 
has been shown yet.  The hypothesis that E4 might contribute to the onset of 
epithelial differentiation and the possibility it can modify the mechanical 
properties of the cell has led us to our current working model depicted in figure 
36. 
This model implies that E4 is expressed at low levels in earlier stages 
in the viral life cycle than shown up to now, though this view is generally 
considered plausible.  It also implies that a low level of E4 can exert a function.  
Subsequently, the high level of E4 found in the late stages of the viral life cycle 
would exert a structural effect on the cell.  This could be simultaneous with an 
effect on the amplification of the viral episome as these two events appear in the 
same cells. 
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The E6 and E7 proteins 
have thickened the basal 
layer by forcing the cell to 
enter S-phase, leading to the 
morphology of a wart.  This 
context does not allow the 
basal keratinocyte to 
differentiate.
Forced 
thickening 
of the 
basal layer 
E4 is made at low levels and 
contributes to the onset of 
the epithelial differentiation, 
allowing the infected cell to 
migrate towards the lumen 
of the cervix and the late 
viral proteins to be made. 
E4 is made in high amounts in 
the upper layers of the 
epithelium and facilitates the 
release of newly made viral 
particles from the terminally 
differentiated keratinocytes. 
: viral episome 
: HPV16 E4 protein 
Fig. 36: Scheme depicting our current model of the dual function of E4 in the life 
cycle of HPV16. 
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